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Abstract 
 
Migraine is much more common in women than in men, and painful episodes 
are linked to the hormonal fluctuations of the menstrual cycle. The MAP kinase 
extracellular-signal regulated kinase (ERK) is activated in experimental models of 
chronic pain, and is also activated by estrogen in sensory neurons. We used an 
established model of inflammatory trigeminal pain, injection of Complete Freund’s 
adjuvant (CFA) into the masseter muscle, to determine whether ERK activation may 
play a role in hormone-related trigeminal pain disorders.  We measured withdrawal 
responses to stimulation of the masseter (V3, primary allodynia) and whisker pad 
(V2, secondary allodynia) using graded monofilaments. Estrogen treatment in the 
presence of inflammation increased withdrawal response to stimulation of either 
masseter or whisker pad compared to inflammation alone, indicating an additive 
effect of inflammation and estrogen on both primary and secondary allodynia.  We 
examined ERK activation in trigeminal ganglia from each treatment group using 
Western blot and immunohistochemistry. Both masseter inflammation and estrogen 
treatment increased ERK activation, and combined treatment had an additive effect. 
Both masseter inflammation and estrogen increased the percentage of pERK 
immunoreactive neurons in divisions 1 and 2 (V1/2), and combined treatment 
increased pERK immunoreactivity in V1/2 compared to inflammation alone.  We 
stereotactically administered ERK antagonist U0126, or inactive control U0124, to 
the trigeminal ganglion of CFA+E2-treated rats.  U0126 decreased withdrawal 
responses to mechanical stimulation of the whisker pad compared to U0124-treated 
rats. Because the secondary allodynia in V2 after inflammation in V3 was reduced by 
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antagonizing ERK activation in the periphery, these data suggest a peripheral 
component to secondary trigeminal allodynia mediated through ERK activation.  
Cellular responses to estrogen can occur through both ‘genomic’ and ‘non-
genomic’ pathways. The novel estrogen receptor GPR30 (G-protein coupled receptor 
30) activates mediators of signal transduction, including ERK.  A goal of this study 
was to determine which estrogen receptor is required for behavioral sensitization. In 
order to determine whether GPR30 is present in neurons of the trigeminal ganglion, 
we performed Western blots for GPR30 on trigeminal ganglion from ovariectomized 
female Sprague-Dawley rats.   Our results show the presence of GPR30 protein in 
the trigeminal ganglion. Immunohistochemistry for GPR30 in trigeminal ganglion 
sections showed that GPR30 immunoreactivity was localized to neuronal cell bodies.  
To determine the subpopulation of neurons that express GPR30, we measured the 
diameters of GPR30 positive and negative neurons.   Neurons expressing GPR30 
were significantly smaller in diameter, suggesting that GPR30 is present in 
nociceptors.  In order to investigate GPR30 expression within sub-populations, we 
co-localized GPR30 with peripherin and NFH using double label 
immunohistochemistry.  GPR30 showed a high degree of overlap with peripherin and 
partial overlap with NFH, indicating that GPR30 is preferentially expressed in 
neurons with unmyelinated axons.   
ERK activation by estrogen in the trigeminal ganglion may occur through 
either the classical estrogen receptor ERα or through GPR30. In order to determine 
which estrogen receptor mediates ERK activation in trigeminal ganglion neurons, we 
examined ERK activation in primary cultures of trigeminal ganglion neurons treated 
with selective agonists for ERα (PPT), ERβ (DPN), and GPR30 (G-1).  ERK was 
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activated by selective agonists for ERα and GPR30, suggesting that activation 
occurs through either receptor. In order to determine which estrogen receptor 
mediates increased trigeminal sensitivity, we used a previously employed behavioral 
model of inflammatory trigeminal allodynia. Ovariectomized female Sprague-Dawley 
rats were injected in the masseter with CFA and subcutaneously administered G-1, 
PPT, or vehicle.  Withdrawal response to stimulation of the whisker pad (V2) was 
measured using monofilaments.  Either G-1 or PPT treatment increased secondary 
allodynia, indicating that both receptors function in trigeminal sensitization in vivo.  
Treatment with estrogen increased expression of ERα but not GPR30, while 
masseter inflammation increased GPR30 but not ERα.  Differential modulation of 
these ERK-coupled receptors by estrogen and inflammation may play a role in 
increased trigeminal pain during periods of falling estrogen.  
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I. Background and Significance 
 
11
Introduction 
 
Disorders of trigeminal pain are among the most common illnesses and 
present a significant burden to the individual and to society.  Migraine headache is 
the most common neurological disorder in the world, affecting 12%-15% of the 
population.  A related disorder, temporomandibular disorder (TMD), which is 
characterized by episodes of pain in the temporomandibular joint and muscles of 
mastication, affects 7-15% of the adult population (Goulet et al., 1995).  Migraine is 
estimated to be the most costly neurological disorder, with an estimated annual cost 
of $16.6 billion in the US and €27 billion in Europe (Andlin-Sobocki et al., 2005).  
Severe migraine is classified as one of the most disabling illnesses by the World 
Health Organization (Menken et al., 2000) and trigeminal pain disorders are 
estimated to account for 9% of lost productivity (Stewart et al., 2003).  Because the 
onset of migraine occurs before the age of 30 in 80% of cases and occurs chronically 
over many years, it carries a high level of morbidity.  Migraine and related trigeminal 
disorders are clearly significant problems that merit basic research. 
Migraine and temporomandibular disorder are both more prevalent in women, 
a characteristic that may be important in understanding their etiology and pathology.  
Migraine is three times more prevalent in women than in men; (Locker and Slade, 
1988; Dworkin et al., 1990; Lipton et al., 1993; Stewart et al., 1994; Yunus, 2002) 
and has a lifetime prevalence of 25% in women (Rasmussen, 1995).  
Temporomandibular joint disorders are at least twice as common in women than in 
men, and 80% of individuals seeking treatment for TMD are women (Dworkin et al., 
1990).  Women experience facial pain primarily in the years between menarche and 
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menopause.  Both migraine and temporomandibular disorder commonly begin 
around the time of menarche, increase during the reproductive years, and regress 
after menopause (LeResche et al., 2005; Lipton and Bigal, 2005), suggesting that 
estrogen fluctuations play a role in these disorders.   Despite substantial clinical data, 
the mechanisms of estrogen’s role in trigeminal pain remain unclear and warrant 
further investigation.  
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 Clinical aspects of migraine 
The most common and well studied trigeminal pain disorder is migraine 
headache.  The migraine episode is a complex constellation of symptoms that 
characteristically involves a severe, unilateral headache with a throbbing or pulsating 
character.  The headache is associated with nausea and sensitivity to light and 
sound, referred to as photophobia, and phonobobia, respectively.  Some patients 
experience auras, disturbances in the visual field, or other sensory phenomena, that 
directly precede the onset of headache.  For this reason, migraine is divided into two 
major categories—migraine without aura and migraine with aura, formerly known as 
common migraine and classic migraine, respectively.  Migraine without aura 
(common migraine) is more common, with an incidence five times that of migraine 
with aura (Rasmussen, 1995).  Although migraine with aura and migraine without 
aura are regarded as distinct disorders (Russell et al., 1996), some patients 
experience both migraine with aura and migraine without aura comorbidly. 
 
Migraine without aura 
Migraine without aura progresses as three phases:  premonitory, headache 
and postdrome phases.  Premonitory symptoms, which occur between two days and 
two hours prior to the onset of headache, are predictive of the onset of migraine 
without aura (Giffin et al., 2003).  A headache diary study found that the most 
commonly reported premonitory symptoms are fatigue, difficulty concentrating and 
stiff neck.   Patients report excitatory states, such as feelings of euphoria or 
irritability, hyperactivity, cravings, thirst, obssessional behavior, hyperactive bowel 
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and bladder, or inhibitory states, which include fatigue, mental slowness, slurred 
speech, anorexia, intolerance to cold, and constipation (Zagami and Bahra, 2005).   
During the headache phase, patients experience pain localized to the 
frontotemporal and ocular regions (Sjaastad et al., 1993).  The majority of headaches 
are unilateral, although bilateral or generalized headaches occur in up to 40% of 
cases (Campbell, 1990).  Pain is described as having a throbbing or pulsating 
character in up to 82% of reported cases (Russell and Olesen, 1996b) and is often 
exacerbated by even minor physical activity (Blau and Dexter, 1981).  This is a 
specific characteristic of migraine that differentiates it from other types of headache 
(Iversen et al., 1990) and is a major reason for its highly disabling nature.  
Non-headache symptoms accompany migraine without aura and include 
nausea, photophobia, and phonophobia in more than 95% of cases (Rasmussen and 
Olesen, 1992).  Non-headache symptoms in the migraineur may be caused by 
increased sensitivity to non-noxious stimuli (Goadsby, 2001).    
Migraine lasts between 4 and 72 hours in 70% of cases (Olesen, 2004).   
Following resolution of the headache, most patients experience non-specific 
symptoms for approximately 24 hours in what is known as the post-drome, or 
‘migraine hangover.’  These include changes in mood, fatigue, muscular weakness 
and anorexia (Blau, 1982). 
 
The diagnostic criteria for migraine without aura, as defined by the 
International Headache Society (IHS), are as follows: 
A. At least 5 attacks fulfilling criteria B–D 
B. Headache attacks lasting between 4 and  72 hours (untreated or unsuccessfully 
treated) 
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C. Headache has at least two of the following characteristics: 
1. unilateral location 
2. pulsating quality 
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical activity 
D. During headache at least one of the following: 
1. nausea and/or vomiting 
2. photophobia or phonophobia   
E. Not attributed to another disorder 
 
Migraine with aura 
Migraine with aura is clinically similar to migraine without aura, with the added 
feature that the headache is immediately preceded by aura.  Aura refers to a 
constellation of neurological symptoms that may include visual, sensory, language, 
or motor changes.  Aura symptoms develop slowly over several minutes and persist 
for less than one hour (Russell et al., 1994).  
Visual aura is reported in 99% of cases  and may present in a variety of 
forms:  photopsia—flashes of white, silver, or multicolored light; scintillating 
scotoma—a blind spot with a shimmering border; or teichopsia—patterns of zigzag 
lines. Positive visual symptoms may be followed by visual scotoma, or loss of part of 
the visual field.  Visual symptoms are usually confined to one hemifield, although 
they may occur bilaterally (Russell and Olesen, 1996a)    
Non-visual sensory phenomena, most commonly parasthesias, accompany 
aura in 30-40% of patients (Manzoni et al., 1985).  Like visual auras, those skin 
sensations, such as burning, prickling, itching, or tingling, with no apparent physical  
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cause are followed by negative symptoms, such as numbness.  Non-visual auras 
tend to be unilateral and involve the perioral region, tongue, and the upper extremity 
(Manzoni et al., 1985). They are migratory, like visual aura, and progress in a wave 
along the skin.  Language aura presents as a speech disturbance and is reported 
less frequently than sensory aura (Olesen et al., 1990).  It is not clear whether the 
speech deficit represents cortical aphasia or dysarthria stemming from paralysis of 
the tongue. Cortical aphasia is the partial or total loss of the ability to communicate 
orally while dysarthria is difficulty in articulating words due to emotional stress or to 
paralysis, incoordination, or spasticity of the muscles used in speaking. 
 
The diagnosis of migraine with aura as defined by the IHS are as follows: 
A. At least 2 attacks fulfilling criteria B–D 
B. Aura consisting of at least one of the following, but no motor weakness: 
1. fully reversible visual symptoms including positive features (eg, flickering 
lights, spots or lines) and/or negative features (ie, loss of vision) 
2. fully reversible sensory symptoms including positive features (ie, pins and 
needles) and/or negative features (ie, numbness) 
3. fully reversible dysphasic speech disturbance 
C. At least two of the following: 
1. homonymous visual symptoms and/or unilateral sensory symptoms 
2. at least one aura symptom develops gradually over ≥5 minutes and/or 
different aura symptoms occur in succession over ≥5 minutes 
3. each symptom lasts ≥5 and <60 minutes 
D. Headache fulfilling criteria B–D for Migraine without aura begins during the aura 
or follows aura within 60 minutes 
E. Not attributed to another disorder 
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Aura is thought to be caused by cortical spreading depression, a 
phenomenon in which cerebral cortical blood flow is transiently decreased to non-
ischemic (oligemic) levels.   Oligemia travels in a wave across the cortex, usually in 
an anterior to posterior direction, preceded by a wave of hyperemia.  There is 
controversy in the migraine field about the role of cortical spreading depression in 
migraine.  Cortical spreading depression and aura may occur in the absence of 
headache, classified as typical aura without headache.   Proponents of CSD believe 
that all migraines involve CSD and that silent auras occur in areas of the cortex in 
which changes in activity are not easily perceptible.  Conversely, others argue that 
aura is an incidental phenomenon found in a minority of headaches.    
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 Sex differences in trigeminal pain disorders  
A characteristic feature of migraine, as well as temporomandibular disorder, 
is a marked sex disparity.  Migraine and TMD are both more prevalent in women 
(Locker and Slade, 1988; Dworkin et al., 1990; Lipton et al., 1993; Stewart et al., 
1994; Yunus, 2002). Women experience facial pain primarily in the years between 
menarche and menopause.  Both migraine and temporomandibular disorder 
commonly begin around the time of menarche, increases during the reproductive 
years, and regress after menopause (LeResche et al., 2005).  Although boys and 
girls have an equal incidence of migraine before puberty, the  post-pubertal 
incidence increases in women and remains stable in men (Bille, 1997).  A similar 
pattern is observed for temporomandibular pain.  Despite the high prevalence of 
TMD and the disproportionate morbidity in women, the prevalance of TMD prior to 
puberty is low and equal between boys and girls (LeResche et al., 1997).  The 
frequency of migraine episodes decreases after menopause following the decline 
and stabilization of ovarian hormones (Neri et al., 1993).  Temporomandibular pain 
also decreases after menopause, and prevelence of TMD is lower for post-
menopausal women than women of reproductive age (Carlsson and LeResche, 
1995). 
 
Menstrual cycle association with pain 
Episodes of trigeminal pain are temporally related to the hormonal 
fluctuations of the menstrual cycle.  Migraine attacks peak around the time of 
menstruation (Welch, 1997; Stewart et al., 2000) and more than 50% of female 
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migraineurs experience headache associated with menstruation (Couturier et al., 
2003).  Menstrual migraine pain is described as more severe than non-menstrual 
migraine by patients (MacGregor, 2000), and is of longer duration and more 
refractory to treatment (Couturier et al., 2003).   Migraine without aura is associated 
with menstruation (common migraine).  Although migraine with aura is not 
associated with menstruation  (Russell et al., 1996), migraine with aura has been 
reported to be associated with high levels of estrogen in estrogen replacement, 
pregnancy, and during the normal cycle (MacGregor, 1999). Pure menstrual 
migraine is defined by the International Headache Society as migraine without aura 
that occurs exclusively on day 1+/-2 of the menstrual cycle (first day of menstruation) 
and at no other time during the cycle.  Migraine that is associated with menstruation 
and also occurs at other points in the cycle is termed menstrually-related migraine 
(Olesen, 2004).  Like headache,  temporomandibular pain varies over the course of 
the menstrual cycle and peaks at menstruation (LeResche et al., 2003).   
Interestingly, temporomandibular pain shows a second mid-cycle increase in pain, 
corresponding to ovulation (LeResche et al., 2003).  This mid-cycle peak does not 
occur in women taking oral contraceptives, which eliminate ovulation  (LeResche et 
al., 2003).  
Although migraines associated with ovulation have not been demonstrated by a 
controlled clinical study, there is some evidence to suggest that they occur (Martin et 
al., 2007a). 
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Estrogen 
Estrogen is implicated as the link between trigeminal pain and the menstrual 
cycle.   Use of estrogen containing oral contraceptives is associated with increased 
headache severity (Kudrow, 1975; Granella et al., 1993).  Temporomandibular pain 
is worse in women taking oral contraceptives (LeResche, 1997) and those with high 
circulating estrogen (Landi et al., 2005).  In post-menopausal women, estrogen 
replacement increases migraine incidence, which varies directly with the estrogen 
dose (Misakian et al., 2003).  Estrogen replacement increases the frequency and 
severity of migraine, as well as analgesic use during episodes of pain (Martin et al., 
2003).  The effect of hormone supplementation on headache is sufficiently common 
for the International Headache Society to specify the term exogenous hormone-
induced headache, which is the diagnosis for women regularly taking exogenous 
hormones who experience new onset of headache or increased frequency or 
severity of headache or for whom headaches remit with cessation of exogenous 
hormones (Olesen, 2004).   
 
The estrogen paradox 
Estrogen withdrawal has long been implicated as the precipitating factor for 
migraine associated with menstruation (Somerville, 1972).  In women who 
experience regular menstrual migraine, preventing the late luteal estrogen decline 
with estrogen supplementation delays the migraine attack until estrogen is 
withdrawn, at which point migraine attack occurs (de Lignieres et al., 1986; 
Dennerstein et al., 1988).  Migraine commonly occurs during the estrogen free 
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interval in women taking cyclical estrogen regimens (Kudrow, 1975).   MacGregor 
and colleagues observed that migraine bears an inverse relationship to urinary 
estradiol across the menstrual cycle, and that attacks are more likely to occur during 
the late luteal phase, in which estrogen drops, than in the follicular phase, in which it 
rises (MacGregor et al., 2006).  In 30-40% of pregnancies, headache occurs during 
the early post-partum period, during which estrogen levels fall (Stein, 1981).   
Although these studies suggest that estrogen is protective, the data are 
complicated.  High estrogen levels have been shown to induce headache 
(MacGregor, 1999) and estrogen exposure is a precondition for migraine with falling 
estrogen (Somerville, 1972).  Moreover, a protective role of estrogen is inconsistent 
with fact that the majority of migraineurs are female.   
 
Sex differences in experimental pain models  
Studies of experimental pain models suggest that females are more sensitive 
to trigeminal nociception than males.  Female rats show greater activity of Aδ and C 
trigeminal afferents than males in response to glutamate injection (Cairns et al., 
2002).  Intradermal capsaicin injection produces greater area and intensity of pain, 
as well increased brush allodynia in females compared to males (Gazerani et al., 
2005).  Similarly, female patients report greater intensity, duration, and area of pain 
than males following glutamate injection into the masseter, suggesting that the same 
effect occurs in humans (Cairns et al., 2001).   
Properties of the trigeminal system change during the estrous cycle.   
Electrophysiological studies have demonstrated increased excitability of the 
trigeminal system during the high estrogen, proestrus phase of the estrous cycle.    
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There is also central nervous system plasticity during the estrous cycle since 
cutaneous receptive fields of central neurons in the spinal trigeminal nucleus 
increase in size during the proestrus phase of the rat estrous cycle (Bereiter and 
Barker, 1980).  Responses to noxious stimuli are also sensitive to the phase of the 
estrous cycle.  During proestrus, spinal trigeminal units increase their receptive field 
sizes and become more responsive to stimulation with bradykinin, suggesting that 
estrogen affects sensitivity of the trigeminal system in vivo (Okamoto et al., 2003).  
Intact cycling rats in proestrus and estrus phases have larger increases in receptive 
fields, and greater rate and magnitude of neuronal  responses to capsaicin compared 
to rats in metestrus and diestrus (Martin et al., 2007b).  Female animals also have 
increased central activation in response to inflammation, as mustard oil injection of 
the temporomandibular joint produces increased c-fos immunoreactivity in the 
nucleus caudalis in proestrus females compared to diestrus female, or male rats 
(Bereiter, 2001).   
Differences in trigeminal pain according to sex and during the estrous cycle 
are related to the influence of estrogen on the trigeminal system.  For example, 
estrogen treatment  of ovariectomized rats increases the receptive field size and 
decreases the activation thresholds of neurons in the spinal trigeminal nucleus 
(Bereiter and Barker, 1975).    Temporomandibular joint afferents are more 
responsive in females compared to males, and this effect is reduced by ovariectomy 
and restored by estrogen replacement (Cairns et al., 2002).  Estradiol treatment of 
ovariectomized rats increases the spontaneous activity and decreases the activation 
thresholds of temporomandibular joint afferents in vitro (Flake et al., 2005).   
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While previous work has demonstrated sex differences in nociception, and 
changes in trigeminal function related to either sex or estrogen state, the effect of 
estrogen on trigeminal nociception has not been investigated using a behavioral 
model.   Accomplishing this would bridge the gap between models that have 
demonstrated sex difference in nociception and models that show changes in 
trigeminal nerve function, showing changes in nociception with estrogen. This is one 
of the goals of the experiments in this dissertation.  
While many studies suggest that estrogen has pro-nociceptive effects, the 
relationship between estrogen and pain is complex, and estrogen has anti-
nociceptive effects in some models.  Ovariectomized female mice display increased 
nociceptive behaviors following formalin injection of the upper lip compared to intact 
females (Multon et al., 2005).  Similarly, aromatase knockout mice, which are unable 
to produce estrogen, show increased nociceptive responses to formalin injection 
compared to wild-type mice.  This difference is eliminated by estrogen replacement, 
suggesting that estrogen is anti-nociceptive or that lack of estrogen is pro-
nociceptive (Multon et al., 2005).  Inflammation of the temporomandibular joint 
prolongs meal duration to a greater degree in males than in females (Bellinger et al., 
2007), suggesting increased pain with mastication.  Interestingly, models that shown 
pro-nociceptive effects of estrogen use formalin injection as a model of pain.  
Although formalin induces inflammation over the long term, it induces pain acutely 
through activation of receptors including TRPA1, a member of the transient receptor 
potential family of ion channels that is involved in sensing irritating chemicals.  The 
anti-nociceptive effects in these models may be related to differential effects of 
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estrogen on the acute phase of pain present in the formalin model, compared to 
chronic inflammatory pain. 
Estrogen may influence nociception through direct action on the trigeminal 
system.   The trigeminal pathway, including the trigeminal ganglion is rich in estrogen 
receptors (Bereiter et al., 2005; Puri et al., 2005). The relationship between serum 
estrogen and ERα receptor expression is complex and appears to be highly 
dependent on both the estrogen level and tissue studied. For example, the number 
of ERα positive neurons is higher in females than in males throughout the trigeminal 
brainstem complex (Bereiter et al., 2005).  In cycling animals, the number of ERα 
positive neurons surrounding the central canal of the trigeminal nucleus caudalis is 
greater in proestrus compared to diestrus (Bereiter et al., 2005), suggesting that 
short term increases in estrogen can upregulate ERα in the trigeminal system.  
Consistent with this concept, a single injection of estradiol increases the percentage 
of ERα labeled pelvic ganglion neurons projecting to the proximal urethra (Zoubina 
and Smith, 2003).  Those changes may result from increased transcription of the 
estrogen receptor in the presence of estrogen or decreased turnover of ERα, as 
steroid receptor ligands have been shown to stabilize steroid receptors (Kemppainen 
et al., 1992).    A goal of the experiments described in this dissertation is to 
investigate changes in receptor expression in the trigeminal ganglion with changes in 
the estrogen state.    
 
The work in this dissertation focused on answering the following questions:    
• How does estrogen affect inflammatory allodynia in the trigeminal system? 
• Which estrogen receptors mediate these changes?    
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• How does the presence of estrogen and inflammation influence expression of 
estrogen receptors? 
 
The Trigeminal Nerve 
Headache and facial pain are conducted by the trigeminal nerve, cranial 
nerve V, which supplies primary sensory innervation to most cranial structures.  The 
trigeminal nerve is composed of a three branch sensory root, which supplies sensory 
innervation to both superficial and deep structures of the face and anterior cranium 
and a motor root, which innervates the muscles of mastication.  Cell bodies of the 
primary afferents are housed in the trigeminal ganglion, located in a recess of the 
middle cranial fossa known as Meckel’s cave. The trigeminal ganglion gives rise to 
the three sensory branches—the ophthalmic (V1), maxillary (V2), and mandibular 
(V3) divisions.  The ophthalmic branch passes through the superior orbital fissure 
and innervates the most superior structures of the head including the orbit, 
conjunctiva and cornea, upper eyelid, frontal sinuses, nasal mucosa, forehead and 
anterior scalp, as well as the meninges and the meningeal vasculature.  The 
maxillary branch (V2) exits through the foramen rotundum and innervates more 
caudal structures including  the lower eyelid, nares, upper cheek, maxillary, ethmoid 
and sphenoid sinuses, and upper palate, upper lip, and the maxillary teeth and 
gums.  The mandibular branch projects through the foramen ovale  and innervates 
the anterior 2/3 of the tongue, the mandible, lower lip and cheek, and the mandibular 
teeth and gums, anterior part of the external ear and part of the lateral scalp.  
Trigeminal afferents enter the central nervous system at the level of the mid-
pons.   In the CNS, neurons that conduct information on discriminative touch project 
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to the principal sensory nucleus of V.   Axons of neurons that conduct nociceptive 
information descend in the spinal trigeminal tract and synapse in the subnucleus 
caudalis in the spinal trigeminal nucleus.  Axons of second order neurons in the 
nucleus caudalis decussate, ascend in the spinothalamic tract, and synapse on third-
order neurons in the ventromedial thalamus.  
The trigeminal nerve also includes a motor root that travels with the 
mandibular nerve and innervates the muscles of mastication—the masseter, 
temporalis, and medial and lateral pterygoid muscles—as well as the anterior belly of 
the digastric muscle, the mylohyoid muscle, the tensor veli palatini, and the tensor 
tympani.   Cell bodies of the motor root fibers are located centrally in the pontine 
trigeminal motor nucleus.  Neurons that receive proprioceptive information on jaw 
position and mechanoreceptive information from the teeth are also located in the 
CNS in the mesencephalic trigeminal nucleus.   
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Figure I-1.   Dermatomes of the 
rat trigeminal nerve 
 
 
 
Cell types 
 Trigeminal ganglion neurons were historically classified as large light (A) and 
small dark (B) cells based on their histological appearance (Gaik and Farbman, 
1973).  Large light (A) cells correspond to neurons with thickly myelinated axons 
(Aα/β), while small dark cells (B) correspond to neurons with thinly myelinated or 
unmyelinated axons.   Medium to large neurons have conduction velocities in the Aβ 
(14-30 m/s) or Aδ (2.2-8 m/s) range.   Aβ are low-threshold mechanoreceptors and 
Aδ are either low-threshold mechanoreceptors, thermoreceptors, or nociceptors.   
Small C fiber neurons are considered to be nociceptors (Lawson, 1992).  Glia, known 
as satellite cells, envelope the soma of neurons in the trigeminal ganglion (Pannese, 
1981). 
Neurons in the trigeminal ganglion are arranged somatotopically.  Cell bodies 
of the mandibular division are located in the lateral and posterior ganglion, and cell 
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bodies of the maxillary and ophthalmic divisions are interspersed in the medial and 
anterior ganglion (Figure I-2).  Although this relationship was described over two 
decades ago using retrograde tracing methods, the trigeminal ganglion has more 
recently been mapped using electrophysiological recording techniques (Leiser and 
Moxon, 2006).    This work described the anatomy of the ganglion in sufficient detail 
to allow identification of the cell bodies that project to each of the three branches.  
Neurons innervating division 3 can easily be distinguished from those innervating 
divisions 1 and 2. 
Figure I-2.  Somatotopic arrangement of the trigeminal ganglion. Montage of 20x 
photomicrographs shows an entire trigeminal ganglion in horizontal cross section 
labeled with pERK (red) and TRPV1 (green).  Divisions 1 and 2 are interspersed in the 
rostral and medial portion of the ganglion (left and top, respectively), and division 3 is 
located laterally and caudally. 
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A two-way street 
 
First order trigeminal nociceptors are pseudounipolar, with axons that project 
bidirectionally to both peripheral tissues and the spinal trigeminal nucleus.   In 
addition to transmitting afferent information from the periphery to the central nervous 
system, trigeminal neurons can also conduct action potentials in an anterograde 
direction, toward the periphery.  Those anterograde action potentials can trigger the 
release of neurotransmitters from the peripheral terminals of trigeminal processes 
(Cuello et al., 1978).  Numerous neurotransmitters and neuropeptides are expressed 
by neurons of the trigeminal ganglion, including CGRP, Substance P, serotonin, and 
neuropeptide Y (reviewed in Lazarov, 2000).   Release of these transmitters can 
have inflammatory consequences in the periphery, inducing vasodilation, plasma 
extravasation, and degranulation of mast cells, a process referred to as neurogenic 
inflammation.   
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Figure I-3.   Schematic of a first order 
trigeminal neuron. Anterograde 
conduction triggers release of 
mediators in the periphery leading to 
vasodilation, plama extravasation 
and mast cell degranulation. 
 
 
 
 
 
Neurogenic inflammation can sensitize peripheral fibers and lead to 
enhanced conduction of nociceptive information to the spinal trigeminal nucleus   
(Strassman et al., 1996). Because the trigeminal ganglion, unlike the dorsal root 
ganglion, contains neurons that project to three separate dermatomes in close 
proximity, intracellular communication may lead to activation across divisions.   
Although it was previously believed that no axo-somatic synapses are present in the 
trigeminal ganglion, more recent evidence suggests that soma can communicate 
through paracrine release of neuropeptides or through gap junctions (Matsuka et al., 
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2001; Thalakoti et al., 2007) and that satellite cells may facilitate communication 
even across ganglionic divisions. 
 
Sensitization in migraine 
Sensitization of the trigeminal system is involved in migraine and other 
disorders of trigeminal pain.  Trigeminal sensitization is evident in the development of 
cutaneous allodynia, or the perception of an innocuous stimulus, such as a soft 
brush, as painful.   Cutaneous allodynia occurs during attacks in the vast majority of 
migraineurs (Burstein et al., 2000a; Burstein et al., 2000b).   
Sensitization during a migraine is thought to begin at the first order trigeminal 
afferent neuron (Levy et al., 2006), mediated by neurogenic inflammation.  According 
to this hypothesis, a stimulus activates trigeminal meningeal afferents and triggers 
the release of neuropeptides that induce vasodilation, plasma extravasation, and 
inflammation, leading to sensitization of trigeminal afferents and migraine pain. The 
theory that neurogenic inflammation causes headache was first proposed by Wolff 
and Chapman more than fifty years ago, based on the observation that ‘headache 
stuff’, subcutaneous aspirates taken from headache patients, could induce 
vasodilation and pain when re-injected at distant sites (Wolff et al., 1953; Chapman 
et al., 1960). The concept that neurotransmitters are released from trigeminal nerve 
terminals and mediate sensitization in headache, was proposed by Moskowitz and 
colleagues (1979), and has subsequently been supported by a number of 
experimental studies.   For example, electrical stimulation of the trigeminal ganglion 
increases cerebral bloodflow (Goadsby and Duckworth, 1987) and induces plasma 
extravasation in the dura, suggesting that trigeminal activation induces a neurogenic 
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inflammatory response (Markowitz et al., 1987).   Dural plasma extravasation is 
reduced by neonatal capsaicin treatment, which destroys nociceptors, indicating that 
those neurons mediate neurogenic inflammation (Markowitz et al., 1987). Stimulation 
of the ganglion releases CGRP and substance P into the cerebral circulation 
(Goadsby et al., 1988), neuropeptides that can mediate neurogenic inflammatory 
processes. For example, intravenous infusion of substance P and CGRP induces 
dural plasma extravasation vasodilation, respectively (Markowitz et al., 1987).  It is 
also known that chemical stimulation of the dura lowers mechanical thresholds of 
dural afferents (Strassman et al., 1996), suggesting that products of neurogenic 
inflammation can sensitize trigeminal neurons.  It has been proposed that sensitized 
trigeminal afferents innervating the meningeal vasculature are activated with the 
pulse, leading to the throbbing character of migraine (Strassman et al., 1996).   
Clinical evidence supports the neurogenic inflammation hypothesis. Serum 
CGRP levels are high during migraine episodes, suggesting the occurrence of a 
neurogenic inflammatory process (Goadsby and Edvinsson, 1993). A study using 
single photon emission computerized tomography (SPECT) to image patients 
experiencing migraine attacks showed accumulation of technetium 99 labeled 
albumin in the meninges, suggesting that menigeal plasma extravasation occurs 
during the course of a migraine (Pappagallo et al., 1999).  Intracranial plasma 
extravasation during migraine has also been imaged using MRI and occurs in 
anatomical correspondence with the headache focus (Knotkova and Pappagallo, 
2007). Notably, all effective anti-migraine therapies to date have been shown to 
inhibit neurogenic inflammation in animal models (Johnson and Bolay, 2006).  
Triptans are the current standard of treatment for migraine. The first triptan on the 
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pharmaceutical market was sumatriptan. Sold as Imitrex and Imigran, sumatriptan is 
administered to elevate low serotonin levels present during the onset of migraine. 
Triptans function as 5-HT (types 5-HT1B  and 5-HT1D) agonists. 5-HT receptors are 
found on cells in the cranial and basilar arteries. Activation of those receptors results 
in their activation and vasoconstriction of the dilated arteries. Sumatriptan has also 
been postulated to abort migraine attacks through reduction in CGRP release, as 
sumatriptan reduces CGRP release from trigeminal neurons and reduces plasma 
CGRP during migraine (Goadsby and Edvinsson, 1993; Durham et al., 2006).  
Peripheral sensitization of primary afferents may lead to central sensitization. 
According to the theory of central sensitization, input from sensitized first-order 
trigeminal afferents sensitizes second-order neurons in the trigeminal nucleus 
caudalis. This lowers the nociceptive threshold for sensory pathways that converging 
on these sensitized second-order neurons.  Chemical stimulation of dural afferents 
enhances the response of second order sensory neurons in the trigeminal nucleus 
caudalis to stimulation of facial skin, taken to indicate central sensitization in the 
trigeminal system (Burstein et al., 1998).  Central sensitization has been postulated 
to explain the common occurrence of allodynia that spreads across dermatomal 
boundaries, referred to as secondary allodynia (Burstein and Jakubowski, 2004).  
Central sensitization has also been proposed to mark the close of the temporal 
window for when triptan therapy is effective (Burstein et al., 2004). 
Although sensitization in migraine is well documented, the events that initiate 
sensitization in migraine are not well defined.  According to one view, championed by 
Moskowitz and colleagues, migraine is a disorder of cortical excitability that activates 
trigeminal afferents, leading to headache.  This hypothesis centers on cortical 
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spreading depression, a wave of cortical depolarization (CSD), followed by a wave of 
hyperpolarization, first described by Leao (1944).  Alterations in cortical blood flow 
accompany CSD, and a wave of hyperemia followed by a wave of oligemia, or 
decreased perfusion.  Cortical spreading depression has been demonstrated during 
the course of migraine (Olesen et al., 1981; Cao et al., 1999; Hadjikhani et al., 2001).   
A link between neurogenic inflammation and CSD was provided by Bolay and 
colleagues who demonstrated that CSD causes dural vasodilation, plasma 
extravasation and c-fos activation in the trigeminal nucleus (Bolay et al., 2002).  All of 
those measures were attenuated by transection of the trigeminal nerve, suggesting 
that CSD induces neurogenic inflammation by activating dural trigeminal afferents 
(Bolay et al., 2002).  Cortical spreading depression is thought to activate trigeminal 
neurons by triggering release of substances from neurons and glia, such as 
potassium, nitric oxide, protons, and glutamate (Moskowitz, 2007). 
Critics of the CSD hypothesis have cited key inconsistencies in CSD as the 
initiating event in migraine, the foremost being that at least 70% of migraineurs do 
not experience aura.  Conversely, aura commonly occurs without headache, and 
abortion of the aura does not affect the headache course, suggesting that aura may 
be a parallel process unrelated to the headache itself (Goadsby, 2001).   
While research on trigeminal sensitization has examined processes in the 
trigeminal braimstem nuclei and peripheral terminals, considerably less attention has 
been paid to potential mechanisms in the ganglion itself.  The trigeminal ganglion is a 
likely site of sensitization, as it is the central structure for peripheral and central 
theories.    Additionally, it is important to note that trigeminal sensitization also occurs 
in temporomandibular disorders, which affect a similar demographic population as 
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migraine, suggesting that a cortical source of trigeminal sensitization is unlikely, as 
these disorders are not accompanied by aura.  The goal of the studies described in 
this dissertation was to investigate sensitization of the trigeminal ganglion with 
inflammation and estrogen, and whether intervention at the ganglion itself affects 
sensitization. 
 
Estrogen receptors 
  
Estrogen receptors α and β 
Estrogen receptor α (ERα) is a member of the steroid/thyroid superfamily of 
nuclear receptors and functions as a ligand-dependent transcription factor that 
modulates gene expression.  ERα contains three major functional domains: a 
sequence-specific DNA-binding domain that recognizes estrogen response elements 
(EREs) in the promoter regions of target genes; a ligand binding domain; and an 
activator function domain that mediates protein-protein interactions.  Upon binding 
estrogen, estrogen receptor α subunits dimerize, allowing interaction with 
transcription factors and estrogen response elements in DNA and ultimately 
producing complex effects on gene expression (Nilsson et al., 2001).  Downstream 
effects of these classical ‘genomic’ actions of ERα require synthesis of new RNA and 
protein, and occur over a period of hours. Although it was believed for a number of 
years that estrogen’s effects are mediated by a single receptor, the characterization 
of estrogen receptor β (ERβ) over a decade ago proved otherwise (Kuiper et al., 
1996).  ERβ is a nuclear receptor that is similar in structure and function to ERα.  
ERβ has a DNA binding domain that is highly homologous to ERα  (Enmark et al., 
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1997) but differs in the activator function domain.  Consequently, although ERβ binds 
to similar genetic elements, its responses to ligands differ from ERα.  For example, 
partial agonists of estrogen receptor α such as tamoxifen are pure antagonists of 
estrogen receptor β (Barkem, et al., 1998). 
 
The rapid signaling estrogen receptor 
 
There are longstanding data confirming that estrogen induces nuclear effects 
over a matter of hours, however, cellular responses to estrogen also occur rapidly in 
a matter of minutes through activation of signal transduction pathways. 
“Nongenomic” effects were first described in 1977 (Pietras and Szego, 1977), but 
research on those pathways lagged behind studies of nuclear actions for many 
years.   The effects of estrogen on signal transduction pathways are known to be 
important in many physiological processes including cardiovascular protection, bone 
preservation, cancer cell proliferation, and neuroprotection.  
There is evidence that non-genomic activity of estrogen can be mediated by 
ERα.  Estradiol has been shown to activate second messenger pathways, including 
the MAPK kinase ERK, in cell lines that express ERα, but not in ERα-negative cells 
(Pedram et al., 2006).  Transfection of cell lines with ERα  confers the ability to 
activate ERK in response to estradiol treatment (Acconcia et al., 2005b).   
Development of the ERα selective agonist PPT (4,4',4''-(4-Propyl-[1H]-pyrazole-
1,3,5-triyl)trisphenol) has facilitated identification of ERα -specific effects.  PPT is a 
potent agonist that binds ERα with a 410-fold higher binding affinity than ERβ 
(Stauffer et al., 2000).   PPT treatment rapidly activates signal transduction 
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mediators in several cell types, providing further evidence for ERα-mediated signal 
transduction (Klinge et al., 2005).  
Non-genomic estrogen effects are thought to be mediated by a form of ERα  
that is sequestered to the cytoplasm or the plasma membrane within a signaling 
complex (Manavathi and Kumar, 2006).  The initial evidence for this concept was 
provided by studies showing that signal transduction is initiated by estradiol 
conjugated to large, membrane impermeant molecules such as bovine serum 
albumin.  For example, rapid ERK activation occurs in response to estradiol-BSA in 
cells that contain membrane-localized ERα (Chen et al., 2004).  Several 
mechanisms have been implicated in targeting ERα to cytoplasmic signaling 
complexes.  Some evidence suggests that post-translational modifications play a 
role.  For example, palmitoylation of ERα  has been shown to be necessary for ERK 
activation in ERα  transfected cells (Acconcia et al., 2004).   A variety of proteins 
have also been implicated in targeting ERα to signaling complexes.  ERα  associates 
with caveolin 1 and 2 which target the receptor to the plasma membrane and allow 
association with a signaling complex (Razandi et al., 2002).  Metastatic tumor 
antigen 1 (MTA1) sequesters estrogen receptor to the cytoplasm and enhances non-
genomic signaling in breast cancer cells (Manavathi et al., 2007).   Although it is 
clear that ERα participates in signal transduction in many systems, whether ERα 
participates in signal transduction in trigeminal neurons has not been investigated. 
   
GPR30 
 An alternative mechanism for rapid signaling by estrogen that has generated 
a great deal of interest is GPR30, a G-protein coupled receptor.  G protein-coupled 
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receptors (GPRs) transduce their signals via G-protein heterotrimers that dissociate 
into free G-subunit protein and G-subunit protein complexes after stimulation with the 
appropriate ligand.  GPR30 was first described in estrogen responsive breast 
adenocarcinoma cell lines (Carmeci et al., 1997), and was known as an orphan 
receptor until recently when it was characterized as a novel estrogen receptor that 
operates exclusively through signal transduction mechanisms (Revankar et al., 2005; 
Thomas et al., 2005; Funakoshi et al., 2006).  Actions of GPR30 can be blocked in 
vitro by pertussis toxin (Filardo et al., 2000), which blocks most receptor-G-protein 
interactions.  Tumor cells that lack both ERα and ERβ but express GPR30 bind 
estrogen with high affinity (Filardo et al., 2000).  GPR30 is expressed at high levels 
in aggressive cancer cells and at much lower levels in nonagressive cells, 
suggesting an involvement of GPR30 in growth of hormone-sensitive tumors 
(Carmeci et al., 1997).    
GPR30 mediates estrogen effects in many cell types.  In endometrial 
carcinoma cells, G-protein inhibitors and GPR30 antisense oligonucleotide  
(Vivacqua et al., 2006a) attenuate c-fos expression induced by estradiol and 
tamoxifen, an ERα  antagonist. GPR30 functions in proliferation of several types of 
tumor cells (Vivacqua et al., 2006b; Vivacqua et al., 2006a; Albanito et al., 2007).   
G-proteins are usually located at the plasma membrane, however, there are 
conflicting data regarding the subcellular location of GPR30.  GPR30 is present in 
the cytoplasm of neurons in the rat hypothalamus (Brailoiu et al., 2007; Sakamoto et 
al., 2007) and localizes to the endoplasmic reticulum in GPR30-transfected COS 
cells (Revankar et al., 2005), in which only cell-permeable estrogens activate 
downstream signaling, suggesting that the intracellular form of GPR30 is functional 
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(Revankar et al., 2007).  By contrast, other studies suggest that GPR30 is localized 
to the plasma membrane like other, previously characterized G-protein coupled 
receptors.  Studies of estrogen binding to GPR30 suggest that the receptor is 
localized to the cell surface in breast cancer cells (Thomas et al., 2005).  Confocal 
analysis of GPR30-expressing hippocampal neurons showed localization of GPR30 
on the plasma membrane (Funakoshi et al., 2006).  GPR30 may traffic between the 
cytoplasm and membrane, as suggested by the translocation of GPR30 to the 
cytoplasm in response to estradiol stimulation of hippocampal neurons (Funakoshi et 
al., 2006).   
One of the targets of ‘non-genomic’ estrogen actions is the MAP kinase ERK.  
Estrogen rapidly activates ERK in neuronal cells, including neuroblastoma cells 
(Watters et al., 1997), cerebral cortical explants (Setalo et al., 2002), cultured DRG 
(Purves-Tyson and Keast, 2004) and trigeminal neurons (Puri et al., 2006).   The 
receptor through which ERK activation occurs in trigeminal neurons has not been 
determined.  There is considerable precedent for the activation of ERK by both ERα 
and GPR30.  Transfection of cells with the GPR30 gene confers the ability of 
estradiol to activate ERK, and estradiol has been shown to activate ERK in cells that 
express GPR30, but not ERα or ERβ (Filardo et al., 2000).  GPR30-mediated ERK 
activation promotes proliferation of ovarian, endometrial, and thyroid tumor cells 
(Vivacqua et al., 2006b; Vivacqua et al., 2006a; Albanito et al., 2007).  Signaling 
through ERα may also activate ERK.  The ERα agonist PPT activates MAPK in 
vascular endothelial cells (Klinge et al., 2005), and ERα transfection allows ERK to 
be activated by estrogen (Acconcia et al., 2005a).   Signaling through either receptor 
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has been demonstrated in the same cell type, as selective agonists for either ERα or 
GPR30 stimulate proliferation of ovarian carcinoma cells (Albanito et al., 2007).  
With the expansion of knowledge of estrogen signaling and receptors there 
are still many questions to be answered about estrogen and trigeminal pain.  
Trigeminal neurons express ERα, but little ERβ (Bereiter et al., 2005).  Whether 
GPR30 is present in the trigeminal system and which estrogen receptor functions in 
trigeminal sensitization are investigated in the experiments described in this 
dissertation.     
 
ERK  
The mitogen-activated protein kinases (MAPKs) are serine/threonine protein 
kinases that mediate cellular responses to a wide variety of signals, including 
hormones, cytokines, and growth factors (Widmann et al., 1999).  One member of 
this family is extracellular-signal regulated kinase, or ERK, also known as p44/42 
MAPK.   ERK mediates a multitude of cellular responses, and is widely studied as a 
promoter of cell division.  The catalytic activity of ERK is activated by dual 
phosphorylation at serine and threonine residues by the upstream kinase 
MAPK/ERK Kinase (MEK).  Upon activation, ERK phosphorylates downstream 
targets in both the nucleus and cytoplasm, including the transcription factors CREB, 
elk-1, and c-myc (Sweatt, 2001). 
ERK has been traditionally viewed as a cell division kinase, however, it is 
also a significant mediator in nociceptive pathways.  Ji and colleagues (Ji et al., 
1999) showed ERK to be a specific marker of nociceptive input that is activated in 
the dorsal horn in a dose dependent manner by noxious stimuli.   Subsequent work 
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has examined ERK activation in nociceptive pathways using pain models.  ERK is 
activated in dorsal root ganglion following nerve injury (Doya et al., 2005), hindpaw 
inflammation (Obata et al., 2003), and by joint movement in the setting of 
inflammatory arthritis (Seino et al., 2006).  Similarly, ERK is activated in the dorsal 
horn by nociceptive stimuli such as pin prick and noxious heat (Ji et al., 1999).   
Following spinal nerve ligation, ERK activation occurs sequentially in dorsal horn 
neurons, microglia, and astrocytes (Zhuang et al., 2005).  These observations have 
led to the widespread use of ERK as a pain marker. 
In addition to being a specific marker of nociceptive input, ERK activation has 
been demonstrated to be mechanistically involved in the development of 
hyperalgesia (increased sensitivity to pain) in models of both inflammatory and 
neuropathic pain.  The selective MEK inhibitor U0126 suppresses mechanical and 
thermal allodynia following chronic constriction of the sciatic nerve, inflammation, or 
formalin injection of the rat hindpaw (Obata et al., 2003)  Using a transgenic mouse 
in which dominant negative MEK is expressed exclusively in neurons, Gereau and 
colleagues demonstrated reduced pain behaviors and thermal hyperalgesia following 
formalin injection, suggesting that ERK activation in neurons is important for 
hyperalgesia (Karim et al., 2006). 
Although the role of ERK activation in pain has been studied extensively in 
the spinal cord and dorsal root ganglion, there is relatively little work on ERK in 
trigeminal pathways.  Existing evidence suggests a similar function of ERK in the 
trigeminal system, as ERK is activated in the trigeminal nucleus caudalis by passive 
jaw movement in the presence of TMJ inflammation (Suzuki et al., 2007) and by 
capsaicin injection of the tooth pulp (Shimizu et al., 2006).   
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 ERK mechanisms 
The mechanism of ERK-mediated pain has not been clarified, and may 
involve cytoplasmic and transcriptional downstream events.  Several molecular 
mechanisms of ERK-mediated hyperalgesia have been proposed.  ERK has been 
shown to increase neuronal excitability through phosphorylation of the Kv4.2  subunit 
of the voltage-gated A-type potassium channel (Adams et al., 2000; Hu and Gereau, 
2003).  In Kv4.2 knockout mice, ERK-dependent forms of pain hypersensitivity are 
absent (Hu et al., 2006).   Nociception mediated by the vanilloid receptor, TRPV1 
may be mediated by ERK, as activated ERK is necessary for facilitation of heat-
induced TRPV1 currents in dorsal root ganglion neurons (Firner et al., 2006).  Genes 
downstream of ERK may also function in its pro-nociceptive effects.   For example, 
antagonizing ERK reduces expression of TRPV1 and NK-1 (Ji et al., 2002a; Obata et 
al., 2004).  In trigeminal neurons, ERK has been shown to promote expression of the 
vasodilatory neuropeptide CGRP, which is implicated in the pathogenesis of 
migraine, suggesting a possible link between ERK and trigeminal pain disorders 
(Durham and Russo, 1998).  
Estrogen treatment activates ERK in primary cultures of dorsal root ganglion 
(Purves-Tyson and Keast, 2004) and trigeminal ganglion (Puri et al., 2006).  Given 
the relationship between ERK activation and nociception, this poses the question of 
whether estrogen contributes to trigeminal pain through ERK activation. The 
estrogen receptor that mediates ERK activation in trigeminal neurons has not been 
investigated.  In other systems, ERK may be activated by either ERα or GPR30.  
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The goal of this dissertation was to investigate whether ERK activation functions in 
estrogen-modified trigeminal nociception. Although estrogen activates ERK in 
sensory neuron cultures, whether ERK is activated by estrogen in trigeminal ganglion 
in vivo has not been determined.  Furthermore, the receptors that mediate ERK 
activation in trigeminal neurons are unknown and are investigated in the studies 
described in this dissertation.  
 
CFA as a model of inflammatory pain 
Inflammation of peripheral tissues is a component of trigeminal pain 
disorders.  During migraine, neurogenic inflammation results in plasma extravasation 
and the release of inflammatory mediators such as leukotrienes, cytokines, 
prostaglandins, and histamine from mast cell granules.  In order to understand the 
responses of sensory neurons to inflammatory conditions, it is useful to create a 
simulated inflammatory milieu in animal models.   
A commonly used model of peripheral inflammation in animals is injection of 
Complete Freund’s Adjuvant (CFA).  CFA is a suspension of heat-killed 
Mycobacterium tuberculosis in paraffin oil that was developed for use in boosting the 
antibody response to vaccines.  CFA is not approved for medical use in humans due 
to the painful inflammatory response it induces, which was bravely described by 
Gould (2000), using himself as an experimental subject (Gould, 2000).   A loss to 
medicine was nonetheless a gain to the field of pain research, as CFA proved to be 
an effective model of inflammatory pain.   CFA, as a depot preparation that remains 
confined to the tissue into which it was injected, produces localized inflammation.  It 
induces a stable inflammatory response over a period of days, allowing pain and its 
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modulators to be assessed over time.   Plasma extravasation occurs and pro-
inflammatory cytokines are produced at the site of inflammation (Watanabe et al., 
2005; Ambalavanar et al., 2006b; Flake et al., 2006).   CFA does not induce systemic 
inflammation, however, as intra-muscular CFA does not increase pro-inflammatory 
cytokines in serum (Watanabe et al., 2005).  Because of these advantages, CFA has 
become a well established pain model used to induce inflammation in a variety of 
sites, including orofacial structures.   
CFA-mediated inflammation increases nociceptive responses to both thermal 
and mechanical stimuli (Ji et al., 2002b), and induces both primary hyperalgesia at 
the site of inflammation, and  secondary hyperalgesia distant from the site of 
inflammation.  These properties have been demonstrated in two models of orofacial 
pain, CFA injection to the temporomandibular joint capsule (Flake et al., 2005; 
Takeda et al., 2005b) and intra-muscular injection into the masseter (Ambalavanar et 
al., 2006a).  CFA administered to either the temporomandibular joint or the masseter 
lowers the withdrawal threshold for mechanical stimulation (Sessle and Hu, 1991; 
Takeda et al., 2004) and induces secondary mechanical hyperalgesia of the whisker 
pad (Takeda et al., 2005b).    
CFA-induced inflammation increases excitability of nociceptive pathways.  
Inflammation of the temporomandibular joint increases excitability to facial 
mechanical stimulation in vivo (Takeda et al., 2006), and the fraction of TMJ-
afferents that respond to capsaicin (Takeda et al., 2005a).  A previous report showed 
increased excitability of TMJ afferent neurons when rats were concurrently 
administered estrogen replacement.  Although peripheral inflammation has been 
demonstrated to induce trigeminal sensitization using behavioral models, and 
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estrogen has been shown to modulate excitability of the trigeminal system using 
electrophysiological approaches, the effect of estrogen on inflammatory nociception 
in the trigeminal system has not been investigated using a behavioral model.  In this 
dissertation we use CFA as an inflammatory agent in order to determine the effect of 
estrogen replacement on trigeminal sensitization induced by peripheral inflammation. 
 
Assessing trigeminal nociception 
 
Although the effect of estrogen on the excitability of trigeminal afferents has 
been evaluated using single unit recording, a useful next step is to investigate the 
effect on nociception. Nociception in animal studies is ideally assessed using 
behavioral models, and many methods have been developed.  Nociceptive assays 
measure spontaneous pain behaviors, thermal nociception, or mechanical 
nociception.  For studying trigeminal pain, it is ideal to assess mechanical sensitivity, 
as patients with trigeminal pain disorders exhibit hypersensitivity of that modality. 
The most established method for assessing mechanical nociception is the use of 
graded monofilaments, which deliver a reproducible mechanical force, allowing 
treatment groups to be compared with respect to either withdrawal threshold or 
withdrawal frequency.  Although monofilament testing has been successfully 
employed in assessing inflammatory and neuropathic pain in the rodent hindpaw 
(Gandhi et al., 2004), those techniques prove difficult to translate to the facial region.  
One of the principal challenges of orofacial testing is that it is necessary to keep the 
rodent’s head stationary in order to reliably test mechanical sensitivity—a moving rat 
makes it exceedingly difficult to reproducibly test the same area, to be confident that 
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a constant stimulus is being delivered, and to discern withdrawal responses from 
spontaneous movements.  Although mechanical testing of the orofacial region using 
graded monofilaments has been described in previous reports (Ren, 1999; 
Ambalavanar et al., 2006a) that method has a significant disadvantage in that it 
involves handling of the animal by the investigator during testing.  Handling of 
experimental subjects alters the behavioral response to stimuli and has been shown 
to induce experimental bias (Chesler et al., 2002), which may explain the large 
withdrawal thresholds (>50g) observed in those models.  One of the goals of this 
project was to develop a reliable and sensitive method for assessing mechanical 
hyperalgesia in the facial region.   In this dissertation, we employ a new model for 
assessing the effect of estrogen on nociception. 
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 Specific Aims of the project 
 Migraine is a highly prevalent and severely disabling disorder.  Although 
migraine episodes are closely associated with estrogen, the mechanisms linking the 
two are poorly understood. This dissertation project had three related aims:  
 
• Although estrogen increases excitability of trigeminal afferents, the 
relationship between estrogen and trigeminal nociception, as measured using 
a behavioral model, has remained unclear.  The first goal of this project was 
to develop a behavioral model for assessing mechanical sensitivity of the 
orofacial region and to use this model to assess the in vivo effects of 
estrogen on inflammatory allodynia. 
 
• The molecular events linking estrogen and nociception are poorly 
understood.  The MAP kinase ERK is a key mediator of inflammatory pain 
and is activated by estrogen in sensory neurons in vitro.  The second goal of 
this project was to investigate whether ERK activation plays a role in 
estrogen-modified nociception.   
 
• The biological significance of non-genomic signaling mediated by estrogen 
receptors has become increasingly clear, particularly with the recent 
discovery of the novel estrogen receptor GPR30.  The third goal of this 
project was to determine which estrogen receptors in the trigeminal ganglion 
function in ERK activation and estrogen-modified nociception.   
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Abstract 
 
Migraine is much more common in women than in men, and painful episodes are linked 
to the hormonal fluctuations of the menstrual cycle.  Migraineurs often present with 
allodynia in the distribution of all three branches of the trigeminal nerve (V1, V2, and V3), 
which is assumed to be centrally mediated. Because trigeminal ganglion neurons 
express estrogen receptors, estrogen may act peripherally to modulate pain responses. 
We used an established model of inflammatory trigeminal pain, injection of Complete 
Freund’s adjuvant (CFA) in the masseter muscle, to study the effect of estrogen 
treatment on inflammatory primary and secondary allodynia/hyperalgesia. 
Ovariectomized female Sprague-Dawley rats were injected in the masseter with CFA or 
saline and subcutaneously administered estradiol valerate or vehicle.  Withdrawal 
response to stimulation of the masseter (V3, primary) and whisker pad (V2, secondary) 
using von Frey filaments was measured. Masseter inflammation, both with and without 
estrogen, increased withdrawal to masseter stimulation 24 and 48 hours following 
injection.  Estrogen treatment in the presence of masseter inflammation increased 
withdrawal response to masseter stimulation at 48 and 72 hours compared to 
inflammation alone.  In order to assess secondary hyperalgesia, mechanical sensitivity 
of the whisker pad was measured 24, 48 and 72 hours following injections.  Masseter 
inflammation increased withdrawal response to whisker pad stimulation 24 hours 
following injection.  In conjunction with estrogen treatment inflammation increased 
withdrawal response compared to CFA alone, indicating an additive effect of 
inflammation and estrogen on secondary hyperalgesia/allodynia. We examined 
activation of extracellular-signal regulated kinase (ERK), a MAPK involved in 
inflammatory pain, in the trigeminal ganglion of each group using Western blot and 
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immunohistochemistry.  Masseter inflammation or estrogen treatment increased ERK 
activation compared to vehicle.  Masseter inflammation in conjunction with estrogen 
treatment increased ERK activation compared to inflammation alone.  
 
In order to determine whether there is increased ERK activation in division 1/2, we 
compared the percentage of neurons in each group containing activated ERK relative to 
total neurons in division 1/2 and division 3.  In division 1/2, either masseter inflammation 
or estrogen increased the percentage of pERK immun4oreactive neurons relative to 
vehicle-treated OVX controls, and concurrent masseter inflammation and estrogen 
treatment increased pERK immunoreactivity in V1/2 compared to inflammation or 
estrogen alone.  In division 3, inflammation, both with and without estrogen, increased 
the percentage of pERK immunoreactive neurons compared to vehicle.  Estrogen 
treatment increased pERK immunoreactivity relative to vehicle. We stereotactically 
administered ERK antagonist U0126, or inactive control U0124, to the trigeminal 
ganglion of CFA+E2-treated rats. Animals treated with U0126 had decreased withdrawal 
responses to von Frey filament stimulation of the whisker pad compared to U0124-
treated rats. Because the secondary allodynia in V2 after inflammation in V3 was 
reduced by antagonizing ERK activation in the periphery, these data suggest a 
peripheral component to secondary inflammatory trigeminal allodynia/hyperalgesia 
mediated through activation of ERK.  
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Introduction 
 
Trigeminal pain disorders, such as migraine and temporomandibular disorders 
(TMDs), are more prevalent in women than in men (Manzoni, 1995; Manzoni et al., 
1995; Dworkin et al., 2002; Lyngberg et al., 2005), which has been attributed to 
estrogen fluctuations  over the course of the menstrual cycle (Somerville, 1972).  
Episodes of trigeminal pain correlate temporally with the menstrual cycle, increasing 
at menarche (LeResche et al., 2005) and declining with cessation of the menstrual 
cycle after menopause and during pregnancy (Lipton and Bigal, 2005).  Trigeminal 
pain in women changes with the menstrual cycle.  Migraine increases during the 
perimenstrual period (MacGregor and Hackshaw, 2004), and TMJ pain increases 
mid-cycle (LeResche et al., 2003) and at menstruation.  Headache and TMDs share 
common features (Glaros et al., 2007), and both may be accompanied by significant 
allodynia (Burstein et al., 2000b; Sarlani and Greenspan, 2003).  Although clinical 
data suggest that estrogen increases susceptibility to trigeminal pain disorders, the 
fall in estrogen at the time of menstruation may precipitate an attack, suggesting a 
complex relationship between estrogen levels and trigeminal pain.   
 
Exogenous estrogens have been shown to have pro-nociceptive effects. Estrogen 
replacement therapy decreases thermal pain thresholds (Fillingim and Edwards, 
2001) and may trigger migraine with aura (MacGregor, 1999).  Use of exogenous 
estrogens, such as hormone replacement therapy or oral contraceptives, increases 
the risk of TMD pain (LeResche et al., 1997).  Sex differences in trigeminal pain 
disorders affecting different cranial sites suggests that the basis for their sex disparity 
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lies in the trigeminal system.  It has been suggested that these effects result from 
direct actions of estrogen on the trigeminal system, which is rich in estrogen 
receptors (Bereiter et al., 2005).  In animal studies, cutaneous receptive fields of 
neurons in the spinal trigeminal nucleus expand in phase with estrogen levels during 
the rodent estrous cycle and with estrogen replacement following ovariectomy 
(Bereiter and Barker, 1975, 1980).  Estrogen replacement in vivo has been shown to 
increase the excitability of acutely dissociated primary trigeminal afferents (Flake and 
Gold, 2005).  However, it has not been determined whether these changes in 
trigeminal excitability translate to allodynia in the awake animal.  
 
The mechanism through which estrogen modulates excitability of trigeminal neurons 
is unclear.  A possible mediator is activation of extracellular signal-regulated kinase 
(ERK), a member of the mitogen-activated protein kinase (MAPK) family.  Activation 
of ERK occurs through a dual phosphorylation event mediated by the upstream 
kinase MAPK/ERK kinase (MEK).  In sensory pathways, ERK phosphorylation is a 
specific marker of nociceptive activation (Ji et al., 1999) and is required for thermal 
and mechanical hyperalgesia in several models of peripheral nerve injury and 
inflammation (Obata et al., 2004b, a).  Estrogen has been shown to activate ERK in 
cultured neurons from dorsal root ganglion (DRG) (Purves-Tyson and Keast, 2004) 
and trigeminal ganglion (Puri et al., 2006), but the effects of in vivo estrogen on ERK 
activation in sensory ganglion has not been examined. 
 
Cutaneous allodynia is common in trigeminal pain disorders (Burstein et al., 2000a; 
Burstein et al., 2000b; Sarlani and Greenspan, 2003) and is an indicator of trigeminal 
sensitization that may be assessed using graded mechanical stimuli.  In the current 
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study, we used a behavioral model of trigeminal inflammatory pain to determine 
whether estrogen modulates mechanical allodynia.  We also investigated the in vivo 
effects of estrogen treatment on ERK phosphorylation and the role of ERK activation 
in the development of orofacial allodynia following inflammation and estrogen 
treatment.   
 
The results of this study support the hypothesis that estrogen-mediated ERK 
activation in the trigeminal ganglion modulates responses to peripheral inflammation, 
and suggest that facial allodynia is not a solely central phenomenon, but is also 
mediated, in part, by peripheral sensitization of the trigeminal ganglion. 
 
Methods 
 
Animals: 60-75 day old virgin female Sprague-Dawley rats (Harlan, Indianapolis, IN) 
were used for all studies.  Rats were maintained on a daily 12 hour light, 12 hour 
dark schedule with ad libitum access to water and food (Harlan Teklad 8604).  All 
studies were conducted in compliance with the National Institutes of Health 
guidelines for the care and use of laboratory animals and the Institutional Animal 
Care and Use Committee of the University of Kansas Medical Center. 
 
Ovariectomy: Rats were anesthetized with 4% isoflurane in compressed oxygen and 
maintained on 1% isoflurane.  Dorsal bilateral incisions were made midway between 
the lower ribs and the iliac crest, and both ovaries were isolated and removed. The 
incision was closed with suture clips and Buprenex was administered (0.1mg/kg).  
Rats were allowed to regain consciousness before returning to the animal facility.  
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 CFA treatment and hormone replacement:  
 
Two weeks following ovariectomy, rats were given a single 50 µl injection of a 
Complete Freund’s Adjuvant (CFA; Mycobacterium tuberculosis H37 Ra; Sigma, St. 
Louis, MO) solution, 1:1 in 0.1M phosphate buffer into the left masseter muscle 
under isoflurane anesthesia.  We used 50 μl of 1:1 CFA solution, a dose that has 
been shown to produce molecular and behavioral effects that last for 3 days (Ro, 
2005; Lee and Ro, 2007).   Control rats were injected with an equal volume of saline.  
Estradiol valerate (E2, Delestrogen, Monarch Pharmaceuticals, Bristol, TN), an 
estradiol conjugate that provides prolonged stable estrogen levels (Oriowo et al., 
1980) 10 μg/kg in sesame oil (100μl), used as a vehicle, was injected 
subcutaneously using a 22 gauge needle during the same surgery as masseter 
injection.  All control rats received sesame oil vehicle.   Post-mortem examination of 
CFA-treated rats and hematoxylin and eosin staining of sectioned facial structures 
revealed granulomatous inflammation confined to the masseter muscle.  We did not 
observe inflammatory pathology upon examination of cranial sites outside the 
masseter, including the whisker pad.   This is supported by other studies using the 
CFA model that demonstrate inflammation confined to the injection site (Ogawa et 
al., 2003; Takeda et al., 2005b; Ambalavanar et al., 2006b). 
 
Orofacial sensitivity assay:   The behavior apparatus is shown in Figure II-1. Rats 
were conditioned to traverse a clear plastic tunnel attached to a behavioral arena (A 
in Figure II-1) in order to gain access to a bottle containing 0.1M sucrose (C in Figure 
II-1).  In this task, the rat must extend its head from a hole in the end of the tunnel in 
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order to sample drops of sucrose solution.  During the drinking task, the rat 
voluntarily held its head in a fixed position, allowing easy and precise access to 
specific areas of the face for mechanical stimulation.  Rats were acclimated to the 
apparatus for 15 minute periods once daily for 5 days.  During each session, the rats 
consume approximately 2 mL sucrose, less than 10% of their total daily water intake.   
This amount of sucrose consumption is less than 1% of the amount required to 
produce antinociceptive effects in adult rats, approximately 1M sucrose ad libitum 
over three to four weeks (Kanarek et al., 2001), and acute effects of sucrose on 
analgesia, present in neonates, disappear by P21 (Anseloni et al., 2002).   The rats 
were not restrained in any way, and the tunnel is large enough for the rat to turn 
around to reenter the arena at any time.  After training, they spent approximately ¼ 
of their time in the testing position when placed in the behavioral arena.  Once rats 
were fully trained and reliably demonstrated acquisition of target behavior, 
withdrawal responses to orofacial mechanical stimulation were assessed using 
graded monofilaments (Stoelting, Wood Dale, IL), a well established method for 
assessing mechanical sensitization in rodents.  Rats were coded and experimenters 
blinded to experimental groups. The behavioral responses were scored as follows: 
no response (scored 0); flinch/orienting reflex (scored 1); partial retraction (scored 2); 
or complete retraction (scored 3).  A flinch/orienting reflex was classified as a 
discontinuation in licking behaviors and orientation toward the stimulus.  A partial 
retraction was classified as retraction of the head away from the reward.  Escape 
back into the tunnel or arena was scored as a full retraction.  A percent withdrawal 
score was calculated for each rat as the sum of response scores divided by the total 
possible score, a score of 3 on all trials.  Withdrawal was assessed in response to 
stimulation of the whisker pad or skin overlying the masseter using 0.16 g and 4 g 
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monofilaments, respectively.  Preliminary studies established that these filaments 
produced withdrawal responses at or below threshold in control rats. Mechanical 
withdrawal responses were measured 24, 48, and 72 hours following CFA and 
estradiol treatments.   
 
Hormone measurements: Blood (1.5 ml) was collected in microcentrifuge tubes by 
cardiac puncture at the time of perfusion. Blood was centrifuged at 7000x g for 5 min, 
and the plasma transferred into fresh tubes.  Serum estradiol levels were measured 
by radioimmunoassay according to the method described in Terranova and Garza 
(Terranova and Garza, 1983).  Mean estradiol values were 37 ± 8 pg/ml for 
estrogen-replaced animals, which corresponds to a proestrus level (Martin and 
Behbehani, 2006) and 4 ±  2 pg/ml for ovariectomized vehicle treated animals. 
 
Western blot: Trigeminal ganglia ipsilateral to the injection site were harvested and 
homogenized in cold lysis buffer (20 mM Hepes buffer, pH 7.4, 10 mM KCl, 1.5 mM 
MgCl2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF, 5  mg/ml pepstatin A, 
10 mg/ml leupeptin and 10 mg/ml aprotinin) using a Dounce homogenizer. The 
homogenate was centrifuged at 12,000 g (10 min, 4 °C) and the supernatant was 
collected.  Total protein concentration was determined with a bicinchoninic acid 
(BCA) assay kit using bovine serum albumin as a standard (Pierce Biotechnology, 
Inc., Rockford, IL).  Proteins were separated using SDS-PAGE on 12%TRIS-HCl 
gels (BioRad, Hercules, CA) and electrophoretically transferred to polyvinylidene 
difluoride membranes.   Membranes were simultaneously probed with rabbit antibody 
specific for the dually-phosphorylated, active form of ERK (p-ERK) (1:200, Cell 
Signaling Technology, Beverly, MA) and goat anti-glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH) 1:1000 (Santa Cruz Biotechnology, Santa Cruz, CA).   
Membranes were rinsed at room temperature in TBS-Tween-20 and IRDye 800 
conjugated anti-goat (Rockland Immunochemicals, Gilbertsville, PA) and Alexa 680 
conjugated anti-rabbit (Invitrogen, Eugene, OR) secondary antibodies were applied 
1:10,000 in blocking buffer for 1 hour at room temperature.  Membranes were rinsed 
at room temperature in Tris-buffered saline containing Tween-20 (TBST) followed by 
TBS and visualized using an Odyssey Infrared Imaging System (LI-COR, Lincoln, 
NE).  For total ERK, membranes were stripped for 30 minutes in a solution of 62.5 
mM Tris HCl, 2% SDS, and 100mM β-mercaptoethanol and reprobed using a mouse 
monoclonal antibody to total ERK (1:1000, #4696, Cell Signaling Technology, 
Beverly, MA) followed by an Alexa 680 conjugated goat anti-mouse secondary 
antibody (1:10,000, Molecular Probes).  Band intensities were determined using 
Odyssey software version 1.0 (LI-COR, Lincoln, NE) and expressed as a ratio of 
pERK/total ERK.    
 
Immunohistochemistry:  Rats were deeply anesthetized with sodium pentobarbital 
(50mg/kg i.p.) and perfused transcardially with 0.1M PBS followed by 4% buffered 
paraformaldehyde.  Trigeminal ganglia were removed, post-fixed overnight in 4% 
buffered paraformaldehyde and cryoprotected in 30% sucrose in 0.1 M phosphate 
buffer pH 7.2.  Ganglia were frozen in Tissue Freezing Medium (Triangle Biomedical 
Science, Durham, NC) at -80° C.  Frozen sections (20μm) through the horizontal 
plane of the trigeminal ganglion were prepared using a cryostat (Carl Zeiss, Inc., 
Oberkochen, Germany).   Horizontal sectioning of the ganglion allows visualization of 
the three anatomic divisions in a single section.  The sections were permeabilized 
and blocked for 1 hour in a solution of 0.3% Triton-X100 and 2% normal goat serum 
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in 0.1M phosphate buffered saline (PBS).  Activated ERK was labeled by incubating 
overnight at 4°C in an antibody specific for the active form of ERK, dually-
phosphorylated at Thr202/Tyr204 of ERK1 and Thr185/Tyr187 of ERK2 (1:200, 
#4376, Cell Signaling Technology, Beverly, MA), followed by 1 hour in AlexaFluor 
568 goat anti-rabbit (1:500, Molecular Probes, Carlsbad, CA).  Some slides were co-
labeled using guinea pig anti-TRPV1 (1:1000, Neuromics, Edina, MN) and 
AlexaFluor 488 goat anti-guinea pig (Molecular Probes).  Slides were coverslipped 
using ProLong Gold anti-fade reagent with DAPI (Molecular Probes).  
 
Microscopy and analysis:  Fluorescent digital images were obtained on a Nikon 
Eclipse 90i upright microscope and Nikon C1 confocal imaging system using a 20x 
objective and a frame size of 1024 × 1024 pixels.  Sections stained with the primary 
antibody omitted were used to control for non-specific fluorescence.  Detector gain 
and laser intensity were set initially using control slides, and all images were then 
collected under the same photomultiplier detector conditions and pinhole diameter.  
This ensured that all neurons considered immunoreactive in images of stained 
sections had fluorescence intensities above background.  Individual images were 
montaged into a single image using Adobe Photoshop CS2 to prevent double 
counting on the image edges and to allow localization of immunoreactivity to 
subdivisions.  In preliminary experiments, all neuronal profiles were immunoreactive 
for total ERK. Neuronal profiles positive for activated ERK and total profiles per 
section were counted from montaged photomicrographs in a blinded fashion. 
Neuronal cells were differentiated from glia by their distinctive large, round 
morphology and pale DAPI staining nuclei.  A minimum of 2000 neurons were 
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counted from at least 2 randomly selected sections from each of 6 animals per 
treatment condition.  
 
Stereotactic injection:  Rats were fixed in a stereotaxic apparatus (Kopf Instruments, 
Tujunga, CA) under isoflurane anesthesia.  The trigeminal ganglion was targeted by 
stereotaxic coordinates (Schneider et al., 1981) and the injection carried out 
according to the method described by Whitehead et al. (Whitehead et al., 2003).  A 
midline incision was made in the scalp and a 1mm burr hole was drilled in the left 
calvarium at 2.5mm lateral and 3 mm posterior to bregma.  A 27-gauge Hamilton 
syringe was lowered slowly into the trigeminal ganglion.  Because central structures 
of the trigeminal pathway are located contralaterally at this level, stereotactic 
injection ipsilateral to testing avoids structures of the tested sensory pathway.  
Correct placement of the needle was confirmed by observing the masseter twitch 
upon the needle entering the trigeminal ganglion.  The MEK inhibitor U0126 or its 
inactive congener U0124 (Tocris Bioscience, Ellisville, MO) 100 μM in 10% DMSO (5 
μl) was injected over 5 minutes.  The scalp was closed with suture clips.  Rats were 
administered Buprenex (0.1mg/kg) and allowed to recover before returning to the 
animal facility.  
 
Statistical analysis: Data were analyzed using Graph Pad Prism version 4.0 software 
(Graph Pad, San Diego, CA).  Behavioral data and immunohistochemical data were 
analyzed by one-way ANOVA using a Bonferroni post hoc test.  Data are presented 
as mean ± SEM, with a P value less than 0.05 considered significant.  
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Results 
 
Estrogen and inflammation additively increase primary and secondary allodynia 
 
In order to determine how estrogen influences mechanical nociception in the 
presence of orofacial inflammation, we used Complete Freund’s Adjuvant (CFA) to 
induce inflammation of the masseter.  CFA injection is an established model of 
inflammatory pain (Ji et al., 2002; Obata et al., 2004a; Duric and McCarson, 2007) 
that can induce widespread mechanical hyperalgesia (Ambalavanar et al., 2006a).  
In order to assess facial mechanical sensitivity, we developed a behavioral method 
based on operant conditioning that allows monofilament testing of the territory 
innervated by the trigeminal nerve (Figure II-1).  Using this method, the 50% 
withdrawal threshold for stimulation of the masseter in preliminary experiments was 
4g.  This model has advantages over other models of mechanical testing of the 
orofacial region that require direct contact between the subject and experimenter 
(Ren, 1999) and result in higher baseline withdrawal thresholds, perhaps due to 
handling (Chesler et al., 2002). 
 
We conducted a preliminary study to determine the monofilament force resulting in a 
50% withdrawal threshold in ovariectomized rats.  A sub-threshold hair was 
subsequently used for the testing of whisker pad and masseter in order to measure 
allodynia.  In order to assess primary allodynia, we stimulated the masseter using a 
4g monofilament (Figure II-2A).  Masseter inflammation, both with and without 
estrogen, increased withdrawal responses to stimulation of the skin overlying the 
masseter 24 and 48 hours following injection (p<0.05).  Estrogen treatment in the 
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presence of masseter inflammation increased withdrawal responses at 48 and 72 
hours compared to inflammation alone (p<0.05).  
 
In order to assess secondary allodynia, mechanical sensitivity of the whisker pad 
was measured using a 0.16g monofilament 24, 48 and 72 hours following CFA 
injection (Figure II-2B).  Masseter inflammation increased withdrawal response to 
whisker pad stimulation 24 hours following injection (p<0.05 compared to vehicle, 
one-way ANOVA).  Estrogen treatment combined with masseter inflammation 
increased withdrawal response to whisker pad stimulation at 24 hours compared to 
inflammation alone (p<0.05) and at 48 hours compared to vehicle (p<0.05).    
 
ERK is activated in trigeminal ganglion by inflammation and estrogen  
 
Because ERK, an established mediator of inflammatory nociception, is activated by 
estrogen in trigeminal ganglion neurons maintained in culture (Puri et al., 2006), we 
explored whether ERK activation contributed to the development of allodynia in our 
behavioral model.  We first examined ERK activation at 24 hours, when CFA-treated 
rats demonstrated mechanical allodynia in the behavioral assay.   
 
We used Western blots to analyze ERK activation in trigeminal ganglion samples 
from rats treated with CFA+E2, CFA, E2, and vehicle-treated rats.  Membranes 
labeled with an antibody specific for the dually-phosphorylated, activated form of 
ERK showed two bands of molecular weight 44 and 42 kD, corresponding to the 
phosphorylated forms of ERK1 and ERK2, respectively.  A representative blot of 
trigeminal ganglion pERK is shown in Figure II-3A.  Either masseter inflammation or 
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estrogen treatment increased ERK1 and ERK2 activation, compared to vehicle 
(Figure II-3B).  Masseter inflammation in conjunction with estrogen treatment 
increased ERK activation compared to inflammation alone (p<0.05). 
 
In order to examine the anatomical distribution of ERK activation, 
immunohistochemically labeled frozen sections of trigeminal ganglion from each 
treatment group—CFA+E2, CFA, E2, and vehicle were compared to determine the 
percentage of neuronal profiles containing activated ERK relative to total neuronal 
profiles per ganglion.  In preliminary experiments, ganglion sections labeled with an 
antibody to total ERK showed immunoreactivity in all neurons.  Activated ERK was 
present in the nuclei and cytoplasm of neuronal soma.     
 
The somatotopic arrangement of the trigeminal ganglion has long been established, 
but recent work has clarified the anatomy of the ganglion to allow identification of cell 
bodies projecting to each of the three branches (Leiser and Moxon, 2006).  Neurons 
innervating division 3 can easily be distinguished from those innervating divisions 1 
and 2 based on anatomic markers (Figure II-4). The neurons with axons innervating 
the masseter, that are exposed to local inflammation following CFA treatment, are 
located in division 3, while the whisker pad is innervated by division 2.  The allodynia 
of the whisker pad following inflammation of the masseter suggests that neurons 
located in division 2 may have increased excitability.  In order to determine whether 
there is increased ERK activation in each division, we compared the change in 
proportion of neurons containing activated ERK in division 1/2 and division 3.  In 
division 1/2, either masseter inflammation or estrogen increased the percentage of 
pERK immunoreactive neurons relative to vehicle-treated OVX controls (p<0.05), 
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and concurrent masseter inflammation and estrogen treatment increased pERK 
immunoreactivity in V1/2 compared to inflammation or estrogen alone (Figure II-6).  
In division 3, inflammation, both with and without estrogen, increased the percentage 
of pERK immunoreactive neurons compared to vehicle (p<0.05, Figure II-6).  
Estrogen treatment increased pERK immunoreactivity relative to vehicle (p<0.05). 
 
Blockade of ERK activation reduces secondary allodynia. 
 
In order to determine whether ERK activation within the ganglion is required for 
trigeminal sensitization, the effect of peripheral administration of an inhibitor of ERK 
activation on allodynia was determined using our behavioral model.  We 
administered U0126 using stereotactic injection, an established method for targeting 
agents to the trigeminal ganglion (Whitehead et al., 2003; Karai et al., 2004).  
Twenty-fours hours after treatment with CFA and E2, a timepoint following the 
development of allodynia, we stereotactically injected the MEK inhibitor U0126, or its 
inactive congener U0124, into the trigeminal ganglion ipsilateral to CFA treatment.  
We assessed withdrawal responses 24 hours following administration of U0126/4.   
U0126 treatment reduced the withdrawal response to whisker pad stimulation 
compared to U0124-treatment (p<0.05, Figure II-7). 
 
Discussion: 
 
The results of this study provide evidence that estrogen increases the duration of 
primary allodynia and both the duration and magnitude of secondary allodynia in the 
region innervated by the trigeminal nerve in a model of trigeminal inflammatory pain.  
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Data also show that inflammation of the masseter increases neuronal ERK activation 
in all three divisions of the trigeminal ganglion, and that estrogen increases ERK 
activation in the trigeminal ganglion in both the presence and absence of peripheral 
inflammation.  Furthermore, the results demonstrate that locally blocking ERK 
activation in the trigeminal ganglion reduces secondary allodynia as shown by 
increased mechanical sensitivity of whisker pad after CFA induced inflammation of 
the masseter.  The results of this study strongly suggest that ERK activation in the 
trigeminal ganglion is important for maintenance of facial allodynia, and that estrogen 
amplifies nociceptive activation of ERK. 
 
Estrogen exacerbates inflammatory trigeminal nociception 
 
The behavioral results show that estrogen increases the duration of primary 
inflammatory allodynia of the facial region.  This is the first study to demonstrate 
enhanced sensitization of the trigeminal territory by estrogen in a behavioral model of 
allodynia.  Estrogen has previously been shown to alter the physiological properties 
of trigeminal neurons.  High estrogen states, in both normal cycling and estrogen 
replacement, increase receptive field sizes in the spinal trigeminal nucleus (Bereiter 
and Barker, 1975, 1980).  The current results are consistent with the data of Flake, et 
al. (Flake et al., 2005) who demonstrated increased excitability of dissociated 
trigeminal afferents three days following estrogen treatment and inflammation of the 
temporomandibular joint. By extending this work to a behavioral model, the results of 
this study suggest that previously described increases in excitability and receptive 
field size result in hyperalgesia in the awake animal.   
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The effect of estrogen on secondary allodynia was tested using mechanical 
stimulation of the whisker pad following inflammation of the masseter, a measure of 
sensitization extending across dermatomal divisions.  Results show that 
inflammation of the masseter increases withdrawal responses to whisker pad 
stimulation, indicating that inflammation of the mandibular branch can sensitize the 
maxillary branch. Secondary hyperalgesia following peripheral inflammation has 
been demonstrated previously.  Widespread sensitization occurs following CFA 
inflammation (Ambalavanar et al., 2006a), and inflammation of the TMJ decreases 
escape threshold and increases excitability of whisker pad afferents in response to 
mechanical stimulation (Takeda et al., 2005b).   
 
Results show that inflammatory secondary sensitization is increased by the addition 
of estrogen.  While estrogen increased the duration of allodynia to primary site 
stimulation, it increased both the duration and magnitude of sensitization of the 
whisker pad.  Estrogen thus appears to spatially broaden the area of allodynia.  
These results may be relevant to cutaneous allodynia, a common clinical 
manifestation of secondary hyperalgesia that occurs in a large proportion of 
migraineurs and TMD patients (Sarlani and Greenspan, 2003; Burstein and 
Jakubowski, 2004).  Cutaneous allodynia varies with the menstrual cycle, and the 
allodynic area is greater in women during both the luteal and menstrual phases of 
the cycle compared to men (Gazerani et al., 2005).  The current findings suggest 
mechanisms by which estrogen could exacerbate cutaneous allodynia during 
episodes of migraine and TMD.   
 
 
81
ERK is activated by estrogen in the trigeminal ganglion 
 
Results show that inflammation of the masseter increases ERK activation in neurons 
of the trigeminal ganglion.  ERK is specifically activated by nociceptive input (Ji et al., 
1999), and neuronal ERK activation mediates hyperalgesia (Karim et al., 2006).  
ERK is activated by peripheral inflammation in dorsal root ganglion and the spinal 
cord dorsal horn  (Doya et al., 2005).  In the trigeminal system, ERK is activated in 
the nucleus caudalis by passive jaw movement in the presence of TMJ inflammation 
(Suzuki et al., 2007) and by capsaicin injection of the tooth pulp (Shimizu et al., 
2006).   
 
Our data provide evidence that estrogen treatment alone can activate ERK in 
sensory ganglia of female rats.  Estrogen can have direct effects on trigeminal 
ganglion neurons, as estrogen receptor α is prevalent throughout the trigeminal 
pathway, including neurons of the trigeminal ganglion (Bereiter et al., 2005; Puri et 
al., 2006).  ERK activation in the presence of increased estrogen in vivo is potentially 
significant in light of the demonstrated role of ERK in mechanisms of pain and 
provides a potential mechanism linking high estrogen states and increases in 
excitability of trigeminal ganglion neurons.  
 
Furthermore, these data show that estrogen administered in the presence of 
masseter inflammation produces a larger increase in ERK activation than 
inflammation alone. An additive effect of estrogen on ERK activation in the context of 
inflammation may have important implications for trigeminal pain.  Neurogenic 
inflammation mediated by peripheral terminals is implicated as an important 
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mechanism of migraine and other disorders of trigeminal pain (Waeber and 
Moskowitz, 2005).  Our results suggest that, during trigeminal pain episodes, ERK 
activation in the trigeminal ganglion induced by peripheral inflammation would be 
increased by a surge in estrogen.  Additional ERK activation induced by estrogen 
may sensitize trigeminal neurons to the degree that a subacute inflammatory 
stimulus becomes painful.  
 
Analysis of ERK activation in the maxillary/ophthalmic division (1/2) shows that 
masseter inflammation increases ERK activation outside the third division of the 
trigeminal ganglion.  This is an intriguing finding, as it shows that peripheral 
inflammation can activate ERK in soma that have no direct contact with the inflamed 
tissue.  These results suggest that ERK activation can occur through intercellular 
communication within the ganglion.   It is possible that neurons containing activated 
ERK can activate the soma of neighboring cells through paracrine signaling.  
Neuropeptides, including CGRP (Ulrich-Lai et al., 2001), are released within the 
trigeminal ganglion from neuronal soma, and may signal to neighboring cell bodies 
(Matsuka et al., 2001).  TMJ inflammation has been shown to increase excitability of 
Aβ neurons projecting to the whisker pad via an NK1 mediated mechanism, 
presumably through local release of substance P (Takeda et al., 2005a).  TNFα 
administration into the TMJ increases p38 MAPK activation throughout the trigeminal 
ganglion by neuron-glia communication through gap junctions (Thalakoti et al., 
2007).  Because the trigeminal ganglion, unlike the dorsal root ganglion, contains 
neurons that project to three separate dermatomes in close proximity, intracellular 
communication may lead to activation across divisions, contributing to trans-
dermatomal allodynia, as seen in this study.   
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 Peripheral ERK activation in trigeminal sensitization 
 
Results of this study show an additive effect of estrogen and inflammation on ERK 
activation within the maxillary/ophthalmic division of the trigeminal ganglion.   
Because of the role of ERK in mediating somatic pain (Obata et al., 2003)  and the 
current behavioral results showing that inflammation and estrogen sensitize the 
orofacial region in an additive manner, we asked whether ganglionic ERK activation 
is involved in changes in facial sensitivity.  The data from these experiments provide 
evidence that delivery of an inhibitor of ERK activation to the trigeminal ganglion 
reduces facial sensitivity, and ERK activation mediates increased peripheral 
sensitization of trigeminal neurons.  Whereas many studies have employed 
intrathecal infusion of MEK inhibitors, in this study, a MEK inhibitor was delivered 
directly to the ganglion in order to examine the role of peripheral activation in the 
primary afferents.  The current results suggest that peripheral ERK activation within 
trigeminal ganglion neurons is an important component of sensitization of the 
orofacial region. 
 
Cutaneous allodynia has been proposed to arise when input from sensitized first-
order trigeminal afferents sensitizes second-order neurons in the trigeminal nucleus 
caudalis, thereby lowering the activation threshold of convergent first-order neurons, 
a phenomenon known as central sensitization.  Chemical stimulation of dural 
afferents enhances the response of second order sensory neurons in the trigeminal 
nucleus caudalis to stimulation of facial skin, taken to indicate central sensitization in 
the trigeminal system (Burstein et al., 1998).  The current observation that secondary 
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allodynia is ameliorated by administration of MEK inhibitor to the trigeminal ganglion 
suggests that ERK activation in neurons of the trigeminal ganglion contributes to the 
maintenance of cutaneous allodynia.  These results are potentially significant to our 
understanding of the pathogenesis of cutaneous allodynia, as they suggest that 
processes within the trigeminal ganglion contribute to cutaneous allodynia.  While 
there is undoubtedly a role for central sensitization in development of allodynia, the 
presence of allodynia across trigeminal dermatomes alone does not prove that 
central sensitization occurs, and, conversely, the existence of central sensitization 
does not preclude the contribution of intra-ganglionic mechanisms. 
 
Several studies have shown reduction of pain-related behaviors by MEK inhibitors 
administered prior to or concurrent with injury.  Our data show that U0126 reduced 
secondary allodynia when administered following the development of sensitization.  
Our results are similar to those of Seino and collegues who showed alleviation of 
pain by U0126 administered by intra-articular injection of the knee following 
development of inflammation in an arthritis model (Seino et al., 2006).  The ability to 
modulate facial pain following development of allodynia has important implications 
for the treatment of migraine, since onset of allodynia signals the close of the 
temporal window during which triptan intervention is effective, ostensibly due to 
central sensitization (Burstein et al., 2004; Burstein and Jakubowski, 2004).  Triptans 
are thought to function by acting on 5HT1B/D receptors in the trigeminal ganglion, 
and sumatriptan reduces CGRP release in cultured trigeminal ganglion neurons 
(Bellamy et al., 2006).  An alternative argument for necessity of early triptan 
treatment is that triptans function by suppression of intra-ganglionic communication, 
and that allodynia signals closure of the window for preventing of cross sensitization 
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of ganglionic divisions.  In that case, pharmacologic approaches targeting the 
periphery, such as ERK antagonism or reducing intraganglionic CGRP release, may 
be viable alternatives. 
 
The results in this study suggest an intra-ganglionic component to facial allodynia.      
Intra-ganglionic sensitization may function in conjunction with central sensitization in 
the generalization of pain during the course of a trigeminal pain episode.  Results 
suggest that estrogen increases secondary sensitization by broadening the 
sensitized area via ERK activation in the trigeminal ganglion. These findings strongly 
suggest the possibility that modulation of signal transduction pathways in the 
periphery following the development of central sensitization may be a useful avenue 
in the management of trigeminal pain. 
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Abstract 
 
Estrogen increases facial allodynia through its actions on activation of the MAP kinase 
ERK in trigeminal ganglion neurons. This goal of study was to determine which estrogen 
receptor is required for behavioral sensitization. Immunohistochemical studies 
demonstrated the presence of estrogen receptor alpha (ERα) in nuclei of larger neurons 
and cytoplasm of smaller neurons, and the novel estrogen receptor G-protein coupled 
receptor 30 (GPR30) in small diameter neurons that also contained peripherin, a marker 
of unmyelinated C-fibers.   Selective agonists for ERα (PPT) and GPR30 (G-1), but not 
ERβ (DPN), activated ERK in trigeminal ganglion neurons in vitro.  Both G-1 and PPT 
treatment increased allodynia after CFA injections in to the masseter of ovariectomized 
Sprague-Dawley rats.  Treatment with estrogen increased expression of ERα but not 
GPR30, while masseter inflammation increased GRP30 but not ERα.  Differential 
modulation of these ERK-coupled receptors by estrogen and inflammation may play a 
role in increased trigeminal pain during periods of falling estrogen.  
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Introduction 
Trigeminal pain disorders such as migraine and temporomandibular disorder (TMD) 
are among the most common neurological conditions (Rasmussen et al., 1991; 
LeResche, 1997; Lipton et al., 2001a) and are two to three times more prevalent in 
women than in men (LeResche, 1997; Lipton et al., 2001b)  The sex disparity in the 
prevalence of trigeminal pain has been attributed to fluctuations in estrogen 
(Somerville, 1972), and trigeminal pain is concentrated during the reproductive 
years, often beginning at menarche and declining after menopause (LeResche et al., 
2005). Trigeminal pain varies across the menstrual cycle, increasing during the 
perimenstrual period (MacGregor and Hackshaw, 2004), and in some cases at mid-
cycle (LeResche et al., 2003).  Although clinical data suggest that estrogen 
increases susceptibility to migraine, the fall in serum estrogen levels at the time of 
menstruation may precipitate an attack, suggesting a complex relationship between 
estrogen levels and the severity of trigeminal pain.   
Exogenous estrogens can also affect nociception in the trigeminal system.  For 
example, estrogen replacement therapy decreases thermal pain thresholds (Fillingim 
and Edwards, 2001) and may trigger migraine with aura (MacGregor, 1999).  Oral 
contraceptive use increases the risk of TMD pain (LeResche et al., 1997).  These 
effects may result from estrogen acting directly on the trigeminal system, which is 
rich in estrogen receptors (Bereiter et al., 2005).   
 
Estrogen may affect a cell through classical nuclear pathways or by signal 
transduction cascades initiated at cell surface membrane receptors.  These estrogen 
receptors may include the well characterized estrogen receptor α (ERα), estrogen 
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receptor β (ERβ), or the more recently described GPR30, a G-protein coupled 
receptor that has been identified as an estrogen receptor  (Revankar et al., 2005; 
Thomas et al., 2005; Funakoshi et al., 2006).  In response to estrogen, GPR30 
activates downstream second messenger pathways, including the MAPK 
extracellular-signal regulated kinase (ERK) (Filardo et al., 2000).  ERK activation is a 
specific marker of nociceptor activation (Ji et al., 1999) that is required for thermal 
and mechanical hyperalgesia in several models of neuropathic and inflammatory 
pain (Obata et al., 2004b, a).  Estrogen increases facial allodynia through activation 
of ERK in trigeminal ganglion neurons (Liverman et al., 2007), but the specific 
receptor mediating these changes has not been determined. 
 
In order to better characterize the effects of estrogen on trigeminal nociception, we 
analyzed the distribution of GPR30 and the classical estrogen receptor ERα in the 
trigeminal ganglion and investigated the effects of selective agonists for ERα or 
GPR30 on ERK activation and facial allodynia. In order to determine how estrogen 
receptors may be regulated by estrogen and inflammation, we examined changes in 
protein expression of ERα and GPR30 in the presence and absence of estrogen and 
peripheral inflammation. Our results support the hypothesis that GPR30 is a 
mediator of estrogen-related trigeminal nociception and indicate that either GPR30 or 
ERα can mediate trigeminal sensitization. Furthermore, differential regulation of 
these receptors by estrogen and inflammation may contribute to increased migraine 
and TMD attacks during the falling estrogen phase of the menstrual cycle. 
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Methods: 
 
Animals: Female Sprague-Dawley rats aged 60-75 days (Harlan, Indianapolis, IN) 
were used for all studies.  Rats were maintained on a daily 12h light, 12 h dark 
schedule with ad libitum access to water and food (Harlan Teklad 8604).  All studies 
were conducted in compliance with the National Institutes of Health guidelines for the 
care and use of laboratory animals and were approved by the Institutional Animal 
Care and Use Committee of the University of Kansas Medical Center. 
 
Ovariectomy: Rats were rapidly anesthetized with 4% isoflurane in compressed 
oxygen, and anesthesia was maintained on 1% isoflurane.  Dorsal bilateral incisions 
were made midway between the lower ribs and the iliac crest, and both ovaries were 
isolated and removed.  Both incisions were closed with suture clips.  Animals then 
received Buprenex (0.1mg/kg) and were allowed to fully regain consciousness before 
returning to the animal facility.  
 
Western blot: Trigeminal ganglia were harvested and homogenized in cold lysis 
buffer (20 mM Hepes buffer, pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM 
EGTA, 1 mM DTT, 0.1 mM PMSF, 5  mg/ml pepstatin A, 10 mg/ml leupeptin and 10 
mg/ml aprotinin) using a Dounce homogenizer. The homogenate was centrifuged at 
12,000 g (10 min, 4 ° C) and the supernatant collected.  Total protein concentrations 
were measured with a bicinchoninic acid (BCA) assay kit using bovine serum 
albumin as a standard (Pierce Biotechnology, Inc., Rockford, IL).  Proteins were 
separated using SDS-PAGE on 12%TRIS-HCl gels (BioRad, Hercules, CA) and 
electrophoretically transferred to polyvinylidene difluoride membranes.   Membranes 
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were subsequently probed with a rabbit anti-GPR30 antibody raised against the C-
terminal domain of human GPR30 (1:500, LifeSpan) or rabbit anti-estrogen receptor 
α (MC-20, 1:300, Santa Cruz Biotechnology, Santa Cruz, CA).  Goat anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 1:1000 (Santa Cruz 
Biotechnology, Santa Cruz, CA) was used to control for sample loading.  Membranes 
were rinsed in TBS-Tween-20 and IRDye 800 conjugated anti-goat (Rockland 
Immunochemicals, Gilbertsville, PA) and Alexa 680 conjugated anti-rabbit 
(Invitrogen, Eugene, OR) secondary antibodies were applied 1:10,000 in blocking 
buffer for 1 hour at room temperature.  Membranes were rinsed in TBST followed by 
TBS and visualized using an Odyssey Infrared Imaging System (LI-COR, Lincoln, 
NE).  Band intensities were determined using Odyssey software version 1.0 (LI-
COR, Lincoln, NE) and reported relative to GAPDH. 
 
Immunohistochemistry:  Two weeks following ovariectomy, rats were deeply 
anesthetized with sodium pentobarbital (50mg/kg i.p.) and perfused transcardially 
with 0.1M PBS followed by 4% buffered paraformaldehyde.  Trigeminal ganglia were 
removed, post-fixed overnight in 4% buffered paraformaldehyde and cryoprotected in 
30% sucrose in 0.1 M phosphate buffer pH 7.2.  Ganglia were frozen in Tissue 
Freezing Medium (Triangle Biomedical Science, Durham, NC) at -80° C.  Frozen 
sections (20μm) through the horizontal plane of the trigeminal ganglion were 
prepared using a cryostat (Carl Zeiss, Inc., Oberkochen, Germany).   Horizontal 
sectioning of the ganglion allows visualization of the three anatomic divisions in a 
single section.  The sections were permeabilized and blocked for 1 hour in  a solution 
of 0.2% Triton-X100 and 2% normal goat serum in 0.1M PBS.  GPR30 was labeled 
by incubating overnight at 4°C with rabbit anti-GPR30 (1:300, LifeSpan Biosciences) 
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followed by 1 hour in AlexaFluor 568 goat anti-rabbit in PBS (1:500, Molecular 
Probes, Carlsbad, CA).  For double-labeling experiments, slides were incubated 
overnight in rabbit anti-GPR30 antibody and either chicken anti-neurofilament H 
antibody (NFH, 1:300, Chemicon, Temecula, CA), chicken anti-peripherin antibody 
(1:300, Chemicon), or mouse anti-ERα antibody (Abcam, 1:100).  AlexaFluor 568 
conjugated goat anti-rabbit was used as a secondary antibody with either AlexaFluor 
488 goat anti-mouse antibody or AlexaFluor 488 goat anti-chicken antibody (1:500, 
Molecular Probes). Slides were coverslipped using ProLong Gold anti-fade reagent 
(Molecular Probes).  
 
Microscopy and analysis:  Fluorescent digital images were obtained using a Nikon 
Eclipse 90i upright microscope and a Nikon C1 confocal imaging system using a 20x 
objective and a frame size of 1024 × 1024 pixels.  Sections processed omitting the 
primary antibody were used to control for non-specific fluorescence.  Detector gain 
and laser intensity were initially set using control slides, and all images were 
subsequently collected under the same photomultiplier detector conditions and 
pinhole diameter.  In double-label experiments, single-antibody labeled sections 
were used to control for channel bleed-through, and multi-channel images were 
acquired using sequential excitation.  For cell counting, individual images were 
montaged into a single image using Adobe Photoshop CS2 to prevent double-
counting at the image edges.  The peak intensity of cells processed in the absence 
of primary antibody determined the threshold for counting a cell as GPR30 positive.  
At least 1000 cells were counted from each of 4 animals for each condition.  At least 
100 neurons were measured per trigeminal ganglion section.   
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Single and double-labeled neurons were counted from digital images to obtain a 
percent score for colocalization of GPR30 with each phenotype marker. The 
percentage of neurons labeled with both markers was determined by counting the 
total number of neurons containing GPR30 immunoreactivity and identifying the 
number of cells labeled with the second neuronal marker.  The same procedure was 
repeated to count the Alexafluor 488 labeled cells.  We determined the percentage of 
peripherin and NFH immunoreactive neurons that also contain GPR30 by dividing 
the number of double-labeled neurons by the total number of neurons that were 
immunoreactive for each marker. The experiment was repeated using two sets of 
independent samples.  
 
Cell diameters were measured using the ruler function of Adobe Photoshop CS2.  
The length of the short and long axes of each neuron in every selected file was 
measured. The diameter of each cell was calculated as the average of length and 
width.  Data are reported as mean ± standard error, with a P value less than 0.05 
using a two-tailed t-test considered significant. 
 
Tissue Culture.  For each experiment, trigeminal ganglia from 4-5 cycling female rats 
were dissected from the base of the skull, rinsed in Hank’s balanced salt solution, 
minced and suspended in digestion medium containing Leibovitz L15 medium with 1 
mg/mL bovine serum  albumin (BSA), 250 U/mL of CLSPA collagenase, 1 U/mL of 
ESL elastase, 5 U/mL of PAPL papain (enzymes from Worthington Biochemical 
Corp., Lakewood, NJ, USA). An equal volume of 30% Stractan (Larex, White Bear 
Lake, MN, USA) in Leibovitz’s L15 was added to the digest. After mixing by 
inversion, samples were centrifuged in a swinging bucket rotor at 4°C or 10 minutes 
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at 500g to enrich the culture for neuronal cells. The pellet of trigeminal cells was 
suspended in a small volume of neurobasal A medium (Gibco/Invitrogen, Carlsbad, 
CA). The cells were plated onto poly-d-lysine coated glass coverslips (Becton 
Dickinson) and maintained in phenol red-free neurobasal A medium containing 10% 
fetal bovine serum, 50 ng/mL nerve growth factor, B27 supplement, and 20 μM 
cytosine arabinoside. Serum and NGF were removed 24 hours prior to 
pharmacologic treatment to reduce baseline ERK phosphorylation. Experiments 
were repeated using at least 5 independent tissue cultures.  
 
In vitro pharmacologic treatments:  We used synthetic 17β-estradiol (Sigma E-2758, 
St. Louis, MO, USA), the most potent and receptor-specific form of estrogen, to study 
the effects of estrogen.  After waiting for 3 days to allow any endogenous estrogen to 
be metabolized, 17β-estradiol was added to the cultures at a final concentration of 
10−8 M. The 17β-estradiol was initially dissolved in ethanol at a concentration of 10−1 
M, then further dilutions were performed in phosphate-buffered saline (PBS) and 
0.1% BSA to achieve a final concentration of 10−8 M, corresponding to a 
physiological range of plasma estrogen.  Cells in the control wells received the 
diluent only.  After 72 hours in culture, cells were treated with 10 nM β-estradiol 
(Sigma, St. Louis, MO), 0.1 M PBS, or selective agonists for ERα— 1,3,5-tris(4-
hydroxyphenyl)-4-propyl-1H-pyrazole (PPT, 10 nM Sigma, St. Louis, MO) (Stauffer et 
al., 2000), GPR30—G-1 (1 μM, Chemical Diversity, San Diego, CA (Bologa et al., 
2006), or ERβ—diarylpropionitrile DPN (100 nM, Sigma).  
 
Immunocytochemistry:  Following pharmacologic treatments, cells were fixed for 10 
min in 4% paraformaldehyde at room temperature, rinsed, then permeabilized for 15 
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minutes in 0.2% Triton X-100 and blocked for 1 h in 1X PBS containing 5% normal 
goat serum.  Coverslips were incubated in rabbit anti-p-ERK (1:200, Cell Signaling 
Technology) and mouse anti-NeuN (1:1000, Chemicon, Temecula, CA)  in 1X PBS 
containing 3% NGS overnight at 4°C followed by washing and secondary antibody 
staining with goat anti-rabbit Alexa Fluor 568 and goat anti-mouse Alexa Fluor 488 
(1:200, Molecular Probes) for 30 min at 25°C.  Images were acquired at 40x 
magnification using a Nikon confocal microscope.  A minimum of 100 cells from three 
independent cultures were analyzed for each experimental group.  Cells 
immunoreactive for NeuN were scored as p-ERK positive or negative by an observer 
who was unaware of the treatment group.   
 
Orofacial sensitivity assay:  Mechanical sensitivity of the orofacial region was 
assessed using the behavioral assay described previously (Liverman et al., 2007).  
Briefly, rats were conditioned to traverse a clear plastic tunnel attached to a 
behavioral arena in order to gain access to a bottle containing 0.1M sucrose.  During 
each session, the rats consume approximately 2 mL sucrose, less than 10% of their 
total daily water intake.   This amount of sucrose consumption is less than 1% of the 
amount required to produce antinociceptive effects in adult rats, approximately 1M 
sucrose ad libitum over three to four weeks (Kanarek et al., 2001).  Importantly, the 
acute effects of sucrose on analgesia, present in neonates, disappear by P21 
(Anseloni et al., 2002).   The rats were not restrained in any way, and the tunnel is 
large enough for the rat to turn around to reenter the arena at any time.  Rats were 
coded and experimenters blinded to experimental groups.  Withdrawal behaviors 
were assessed in response to stimulation of the whisker pad or skin overlying the 
masseter using 0.16 g and 4 g monofilaments, respectively.  Preliminary studies 
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established that these filaments produced withdrawal responses at or below 
threshold in control rats. Mechanical withdrawal responses were measured 24, 48, 
and 72 hours following CFA in combination with selective agonist treatments.   
 
CFA and selective agonist treatment:  Two weeks following ovariectomy, rats were 
given a single 50 µl injection of Complete Freund’s Adjuvant (CFA; Mycobacterium 
tuberculosis H37 Ra 1 mg/ml; Sigma, St. Louis, MO) emulsion, 1:1 in 0.1M 
phosphate buffer into the left masseter muscle under isoflurane anesthesia.  This 
dose produces molecular and behavioral effects that last for 3 days (Ro, 2005; Lee 
and Ro, 2007) when injected into the masseter.   Control rats were injected with an 
equal volume of isotonic saline.  Estradiol valerate (E2, Delestrogen, Monarch 
Pharmaceuticals, Bristol, TN, 10 μg/kg in 100μl sesame oil vehicle) was injected 
subcutaneously using a 22 gauge needle during the same surgery as CFA injection 
into the masseter.  Estradiol valerate is an estradiol conjugate that provides 
prolonged stable serum estrogen levels (Oriowo et al., 1980).  All control rats 
received sesame oil vehicle.   Post-mortem examination of CFA-treated rats and 
hematoxylin and eosin staining of sectioned facial structures revealed granulomatous 
inflammation confined to the masseter muscle.  We did not observe inflammatory 
pathology upon examination of cranial sites outside the masseter, including the 
whisker pad.   This is supported by other studies using CFA injection of TMJ and 
masseter that demonstrate inflammation confined to the injection site (Ogawa et al., 
2003; Takeda et al., 2005; Ambalavanar et al., 2006b).  Behavioral experiments were 
conducted with  three groups of 10-12 rats.  Each rat was given a CFA injection into 
the masseter muscle and either the ERα−selective agonist PPT, (Sigma, St. Louis, 
MO, 1mg/kg dissolved 1 μg/ul in sesame oil), the GPR30-selective agonist G-1 
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(Chemical Diversity, San Diego, CA, 1mg/kg dissolved 1 μg/ul in sesame oil), or 
sesame oil vehicle by subcutaneous injection between the scapulae using a 22 
gauge needle.  G-1 is a recently characterized selective agonist for GPR30 (Bologa 
et al., 2006).  PPT is a potent ERα agonist that binds ERα with a 410-fold higher 
binding affinity than ERβ (Stauffer et al., 2000), and DPN is a selective agonist for 
ERβ that binds ERβ with a 70 fold higher affinity than ERα (Meyers et al., 2001).   
The PPT dose was selected according to Harris, 2002.  G-1 has been shown to 
induce sensitization at a range of doses spanning several orders of magnitude (Kuhn 
et al., 2008).    
 
Statistical analysis 
Data were analyzed using Graph Pad Prism version 4.0 software (Graph Pad, San 
Diego, CA) Behavioral data and immunocytochemistry were analyzed using one-way 
ANOVA with a Bonferroni post-hoc test.  Western blots and cell size measurements 
were compared using two-tailed unpaired t-tests.  Data are presented as mean +/- 
SEM, with a P value less than 0.05 considered significant.  
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 Results 
 
GPR30 expresssion in rat trigeminal ganglion 
 
In order to determine whether GPR30 protein is expressed in the trigeminal ganglion, 
we performed Western blots on homogenates of trigeminal ganglia from 
ovariectomized female Sprague-Dawley rats using a GPR30-specific antibody.  
Membranes showed a single band of an appropriate molecular weight (Figure III-1) 
that was eliminated by preincubation of the antibody with the immunizing peptide, 
indicating that the antibody is specific for GPR30 (data not shown).   
 
GPR30 expression in trigeminal neuron subpopulations 
 
To determine the trigeminal ganglion cell types that express GPR30, we performed 
immunohistochemistry on frozen sections using the same GPR30 antibody used in 
Western blots. GPR30 immunoreactivity was localized to neurons (Figure III-2).  We 
observed immunofluorescence throughout the neuronal cytoplasm of positively 
labeled cells.  Immunofluorescence was also specific for GPR30, as preincubation of 
the antibody with the immunogen peptide eliminated staining (data not shown).   
 
To characterize the expression of GPR30 within trigeminal ganglion sub-populations, 
we used double-label immunohistochemistry to determine the colocalization of 
GPR30 with peripherin, a marker of neurons with unmyelinated axons and 
neurofilament H (neurofilament 200), a marker of neurons with myelinated axons 
112
(Figure III-2).  The localization of GPR30 expression was primarily restricted to 
neurons with unmyelinated axons.  Seventy-six percent of GPR30-positive neurons 
were peripherin positive, and 73% of peripherin-positive neurons were 
immunoreactive for GPR30.  Thirty four percent of GPR30 positive neurons were 
NFH positive, and GPR30 was present in 32% of NFH positive neurons. 
 
In order to investigate the neuronal phenotypes that express GPR30 in the trigeminal 
ganglion, we measured the diameters of cells that were immunoreactive and non-
immunoreactive for GPR30.  GPR30 immunoreactivity was skewed toward small 
diameter neurons (Figure III-3), although GPR30 was expressed across a broad 
range of cell sizes.  The average diameter of GPR30-positive cells (23.9 ± 0.8 μm) 
was significantly smaller (p<0.01) than the average diameter of GPR30-negative 
cells (28.9 ± 1.04 μm).  
 
 
ERα immunohistochemistry 
 
Because ERα is a putative mediator of estrogen-modified nociception, we used 
immunohistochemistry to label ERα in the trigeminal ganglion.  We observed 
prominent ERα immunoreactivity throughout the trigeminal ganglion that was 
localized to neurons.  ERα was present in both nuclear and cytoplasmic 
compartments (Figure III-4A).  By visual inspection, cytoplasmic ERα 
immunoreactivity was present prinicipally in small neurons, while nuclear ERα was 
located in larger cells.  In order to quantify the distribution of immunoreactivity, we 
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measured the diameters of ER immunoreactive cells for both the cytoplasmic and 
nuclear ERα  populations. Figure III-4B shows the diameters of neurons 
immunoreactive for cytoplasmic and nuclear ERα.  Cells expressing cytoplasmic 
ERα had a mean diameter of 19.1 +/- 0.3 μm, which was significantly smaller 
(p<0.05) than the diameter of cells expressing nuclear ERα, with a mean diameter of 
31.2 +/- 0.4 μm.   
 
Colocalization of GPR30 and ERα 
 
We used double-label immunohistochemistry to determine the co-localization of 
GPR30 and ERα.   ERα and GPR30 were present in distinct but partially overlapping 
populations.  We observed neurons that expressed both GPR30 and ERα, and 
neurons that expressed only ERα  or GPR30 (Figure III-5).  Ten percent of trigeminal 
ganglion neurons expressed both GPR30 and ERα, 22% expressed ERα, and 35% 
expressed GPR30.  
 
ERK activation by selective agonists for ER and GPR30  
 
Estrogen has been demonstrated to activate ERK in primary cultures of dorsal root 
ganglion and trigeminal ganglion neurons (Purves-Tyson and Keast, 2004; Puri et 
al., 2006) and in the rat trigeminal ganglion in vivo (Liverman et al., 2007).  In order 
to determine which estrogen receptor mediates ERK activation, we assessed ERK 
activation in primary trigeminal ganglion cultures following application of agonists 
selective for GPR30, ERα, or ERβ.  G-1 or PPT increased the percentage of p-ERK 
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positive neurons compared to vehicle (Figure III-6).   Activated ERK immunoreactivity 
was present in 67% of PPT-treated neurons and 64% of G-1 treated neurons 
compared to 18% with vehicle treatment.  DPN treatment did not significantly 
increase ERK activation. 
  
Selective agonists for GPR30 and ERα increase orofacial sensitivity 
 
We previously demonstrated that estrogen increases facial allodynia through 
activation of ERK (Liverman et al., 2007).  To better characterize which estrogen 
receptor mediates increased trigeminal sensitization, we examined the effects of 
PPT and G-1 on facial mechanical nociception in the presence of orofacial 
inflammation using a rat behavioral model.  We used Complete Freund’s Adjuvant 
(CFA), an established model of inflammatory pain (Ji et al., 2002; Obata et al., 
2004a; Duric and McCarson, 2007) that can induce widespread mechanical 
hyperalgesia (Ambalavanar et al., 2006a), to induce inflammation of the masseter. 
 
In order to assess facial mechanical sensitivity, we developed a behavioral model 
based on operant conditioning that allows monofilament testing of the orofacial 
region.  We conducted a preliminary study to determine the monofilament force 
resulting in a 50% withdrawal threshold in ovariectomized rats.  A sub-threshold 
filament was subsequently used for the testing of whisker pad in order to measure 
allodynia.  In order to assess secondary allodynia, mechanical sensitivity of the 
whisker pad was measured using a 0.16g monofilament 24, 48, and 72 hours 
following CFA injection and selective agonist treatment.  Injection of either PPT or G-
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1 enhanced withdrawal responses in the setting of peripheral inflammation at 24 
hours compared to vehicle-treated controls (Figure III-7).   
 
Estrogen effects on expression of GPR30 and ERα 
 
In order to determine whether estrogen treatment changes the protein content of 
estrogen receptors in the trigeminal ganglion, we used Western blot to compare ERα 
and GPR30 protein levels in trigeminal ganglion samples from OVX and OVX+E2 
rats.  We observed a significant increase in ERα in ganglia from estrogen-treated 
animals compared to vehicle-treated controls (Figure III-8).  Two size variants of 
ERα were present in the trigeminal ganglion, at 66 kD and 90 kD.  Both variants 
were upregulated by estrogen, 1.81-fold and 1.76-fold respectively.  GPR30 protein 
content was not significantly altered in the trigeminal ganglion by estrogen 
replacement. 
 
Inflammation effects on expression of GPR30 and ERα 
 
In order to determine whether peripheral inflammation of the trigeminal nerve 
alters expression of ERα and GPR30 in the trigeminal ganglion, we compared 
ERα and GPR30 protein levels using Western blots of trigeminal ganglion 
samples taken from groups of ovariectomized rats with inflamed or normal 
masseter muscles.  Inflammation of the masseter increased GPR30 
expression 2.25 fold in the trigeminal ganglion compared to vehicle-treated 
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controls, whereas it did not significantly change ERα expression in the 
trigeminal ganglion (Figure III-9). 
 
 
Discussion: 
 
Although it is well established that estrogen modifies orofacial pain, the receptors 
mediating these changes have remained unclear.  Results of the current study 
support roles for both the novel estrogen receptor GPR30 and estrogen receptor α in 
estrogen-modified nociception.  Furthermore, our data show that these receptors are 
differentially regulated by estrogen and inflammation, which may have important 
implications for the modulation of trigeminal pain during the menstrual cycle.  
 
GPR30 is present in the trigeminal ganglion 
 
Our results show that GPR30 is present in the trigeminal ganglion of female rodents.  
GPR30 expression was localized to small, unmyelinated, peripherin-positive 
neurons, suggesting that GPR30 is localized to nociceptors in the trigeminal 
ganglion. Identification of a novel estrogen receptor in the sensory pathway is 
potentially significant to estrogen-modified trigeminal sensitization.  Female animals 
are more sensitive to trigeminal nociception than males (Bereiter, 2001; Cairns et al., 
2002) especially during the high estrogen phase of the estrous cycle (Okamoto et al., 
2003; Martin et al., 2007).  Furthermore, estrogen replacement increases excitability 
of trigeminal afferents and enhances inflammatory sensitization of the trigeminal 
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system (Bereiter and Barker, 1980; Flake et al., 2005; Liverman et al., 2007).  The 
presence of GPR30 in cells likely to be nociceptors suggests that GPR30 is a 
possible mediator of estrogen-modulated pain sensitization.   
 
ERα is present in both cytoplasmic and nuclear compartments 
 
ERα immunoreactivity was present in both cytoplasmic and nuclear compartments of 
trigeminal ganglion neurons.  Previous studies of ERα in the rat trigeminal ganglion 
have restricted analyses to cells with nuclear labeling, discounting the potential 
importance of cytoplasmic estrogen receptor immunoreactivity (Bereiter et al., 2005; 
Puri et al., 2006).  The results of this study demonstrate a size differential based on 
subcellular localization, with cytoplasmic ERα predominant in smaller neurons and 
nuclear ER in larger neurons.   These results are intriguing in light of the dual role of 
ERα in both classical nuclear pathways and ‘non-genomic’ actions through signal 
transduction pathways.  ERα-dependent activation of signal transduction molecules 
is thought to originate from receptors sequestered in cytoplasmic signaling 
complexes (Manavathi and Kumar, 2006).  The current results suggest that this 
mechanism predominates in nociceptive neurons, while, in larger diameter neurons, 
where ERα immunoreactivity is localized to the nucleus, estrogen may preferentially 
function through direct genomic mechanisms. Previous studies have shown that 
estrogen modifies nociception through non-genomic mechanisms by activating ERK 
in the trigeminal ganglion (Liverman et al., 2007).  The present results suggest that 
cytoplasmic ERα in small diameter neurons contributes to this process. 
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ERα and GPR30 are expressed in distinct populations 
 
Because the present data show that cytoplasmic ERα and GPR30 are expressed in 
small-diameter neurons, the co-localization of ERα and GPR30 in the trigeminal 
ganglion was analyzed.  Results show that ERα and GPR30 are present in distinct, 
but partially overlapping, neuronal populations, and that the majority of small 
trigeminal neurons express one of these receptors.  Expression of either ERα or 
GPR30 by the majority of nociceptors in the trigeminal ganglion suggests a basis for 
the high sensitivity of the trigeminal system to estrogen.    
 
ERK is activated through GPR30 and ERα 
 
Results show that selective agonists for either GPR30 or ERα induce rapid ERK 
activation in trigeminal ganglion neurons, suggesting that ERK activation mediated 
by estrogen (Puri et al., 2006; Liverman et al., 2007) can occur through either 
estrogen receptor α or GPR30.  Furthermore, these data show that trigeminal 
GPR30 is functional in activating signal transduction pathways in trigeminal ganglion 
neurons, which may be relevant to estrogen’s modification of nociception. 
 
There is considerable precedent suggesting that ERK can be activated by either 
ERα or GPR30 in many estrogen sensitive cell types (Vivacqua et al., 2006b; 
Vivacqua et al., 2006a; Albanito et al., 2007), and signaling through either receptor 
has been demonstrated in the same cell type (Albanito et al., 2007).  
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Estrogen receptor-evoked activation of ERK may be significant to the pathogenesis 
of estrogen-modified sensitization.  ERK phosphorylation in sensory neurons is a 
specific marker of nociceptive stimulation (Ji et al., 1999) and a mediator of 
mechanical hyperalgesia in pain models of peripheral nerve injury and inflammation 
(Obata et al., 2003; Obata et al., 2004c).  As estrogen increases mechanical 
allodynia of the orofacial region through activation of ERK (Liverman et al., 2007), 
ERK phosphorylation resulting from ERα or GPR30 activation may be important to 
the pathogenesis of trigeminal pain.  Activation of ERK in the unmyelinated neurons 
expressing ERα or GPR30 could lead to increases in neuronal excitability resulting in 
allodynia.   
 
GPR30 and ERα participate in trigeminal sensitization 
 
The results of the current study demonstrate that selective agonists for either GPR30 
or ERα enhanced secondary mechanical allodynia of the orofacial region, suggesting 
that both GPR30 and ERα are capable of mediating pro-nociceptive responses to 
estrogen in the trigeminal system.  By identifying GPR30 as a putative modulator of 
sensitization in the trigeminal system, the current results reveal an increased 
complexity of pro-nociceptive effects of estrogen in the trigeminal system.  The 
presence of GPR30 in the trigeminal ganglion presents a novel pathway through 
which estrogen may modulate the activity of sensory neurons, and which may be 
relevant to effects of hormonal fluctuations on migraine and facial pain.   
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ERα is increased by estrogen while GPR30 is increased by inflammation 
 
Results show that inflammation in the trigeminal distribution upregulates GPR30 
protein in the trigeminal ganglion.  Although the effect of inflammation on GPR30 
expression has not been previously addressed, estrogen and inflammation have 
been shown to have additive effects on trigeminal excitability and nociceptive 
responses (Cairns et al., 2002; Flake et al., 2005; Martin et al., 2007).  Increased 
expression of GPR30 in the presence of inflammation may lead to enhanced 
estrogen signaling.    The current data suggest that peripheral inflammation during 
episodes of trigeminal pain may increase GPR30 and lead to enhanced modulation 
of nociception by estrogen.  Furthermore, since inflammation did not modify 
expression levels of ERα, peripheral trigeminal inflammation may shift the balance of 
estrogen signaling in trigeminal neurons toward GPR30.   
 
Data show that the presence of estrogen increases levels of ERα protein in the 
trigeminal ganglion.  The relationship between serum estrogen and ERα receptor 
expression is complex and appears to be highly dependent on both the estrogen 
level and tissue studied, but these data are consistent with several previous studies 
showing that estrogen increases ERα in sensory neurons (Zoubina and Smith, 2003; 
Bereiter et al., 2005).  GPR30 expression, by contrast, was not changed by estrogen 
replacement.  This result is consistent with studies of hamster ovary showing that 
GPR30 expression was not changed by estrogen replacement (Wang et al., 2007).  
 
The current results suggest two potential mechanisms that may contribute to the 
paradoxical effect of falling estrogen leading to increased pain.  First, ERK activation, 
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mediated by GPR30 and ERα, may be involved in sensitization during periods of 
decreased serum estrogen.  ERK may be activated intermediate doses of estrogen, 
but not by high doses of estrogen, suggesting that as estrogen concentrations drop 
during the menstrual phase, ERK activation may increase (Kuroki et al., 2000).  
Second, differential regulation of GPR30 and ERα by estrogen and inflammation 
may contribute to increased pain during periods of falling estrogen.  The results of 
this study show that inflammation in the trigeminal region increases GPR30 
expression levels, shifting the balance of estrogen signaling toward GPR30.  In 
addition, falling serum estrogen concentrations would downregulate ERα expression 
levels, further shifting estrogen signaling toward GPR30.  Since the neuronal 
populations that express ERα and GPR30 are largely distinct, a decrease in serum 
estrogen concentration in the context of peripheral inflammation could shift estrogen 
signaling to favor the population that expresses GPR30, which is predominately 
composed of likely nociceptive neurons.  Although the downstream genes 
differentially induced by activation of GPR30 and ERα are not completely 
characterized, they may include pro-nociceptive genes.   
 
In conclusion, the results of this study demonstrate that estrogen can modulate 
trigeminal nociception through both the GPR30 and ERα pathways and provide new 
insight into the complex relationship between estrogen and trigeminal pain. 
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 The first aim of this project was to assess the in vivo effects of estrogen on 
inflammatory allodynia.  An initial challenge in accomplishing this aim was to 
establish a reliable method for assessing mechanical allodynia in the facial region. 
Although there are established methods for evaluating mechanical hyperalgesia in 
other regions of the body, such as the hindpaw, these techniques prove difficult to 
apply to the facial region due to the challenge of producing a stationary rat without 
the use of restraint.  The constant exploratory behavior of the rat when exposed to a 
novel environment such as a testing arena makes it difficult to reproducibly test the 
same area, to be confident that a constant stimulus is being delivered, and to discern 
withdrawal responses from spontaneous movements.  Although mechanical testing 
of the orofacial region using graded monofilaments has been described in previous 
reports (Ren, 1999; Ambalavanar et al., 2006), those methods require the 
investigator to handle the animal during testing, which alters behavioral responses to 
stimuli (Chesler et al., 2002).    
We overcame those problems by using an operant model in which rats are 
trained to drink sweetened water from a standard rodent water bottle.  During this 
task, the rat holds its head in a fixed position and focuses its attention on obtaining 
the reward.  This provides increased precision, as the fixed position of the rats head 
allows the investigator to precisely access specific regions of the face using 
monofilaments and eliminates variability in the angle of testing.   Furthermore, the 
operant behavior allows the rat to be tested without direct contact by the investigator, 
which increases the sensitivity of the assay.  Models in which rodents are held by the 
investigator during testing produce withdrawal thresholds that are considerably 
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higher, >50g for masseter stimulation, than those observed using the present 
method, approximately 4g.  Moreover, although previous methods of trigeminal 
testing assess whether or not stimulation elicits a response, our method also scores 
the magnitude of the response.  In doing so, this method is sensitive to changes in 
the degree of sensitization.  
We anticipate that the operant method of trigeminal mechanical testing 
developed in this project will allow trigeminal mechanical nociception to be assessed 
with increased sensitivity, which will prove valuable to future study of trigeminal pain 
and for evaluating potential therapeutic interventions.  
The behavioral data collected using this method provide evidence that 
estrogen treatment of ovariectomized rats increases both primary and secondary 
allodynia of the orofacial region.  Specifically, estrogen increases the duration of 
primary allodynia, and increases both the duration and magnitude of secondary 
allodynia.   More than two decades ago, the studies of Bereiter demonstrated that 
estrogen increases the size of trigeminal receptive fields (Bereiter and Barker, 1975, 
1980). The current findings support a role for estrogen in increasing the size of the 
sensitized area in the presence of inflammatory nociception. Several reports indicate 
that estrogen has an additive effect on the increases in trigeminal excitability induced 
by inflammation (Cairns et al., 2002; Okamoto et al., 2003; Flake et al., 2005; Martin 
et al., 2007).   Our data suggest that these estrogen-induced increases in excitability 
translate to enhanced nociception.  Although estrogen has been shown to induce 
excitability in the absence of inflammation (Bereiter and Barker, 1980; Flake et al., 
2005), there is no increase in trigeminal sensitization with estrogen alone.  It is 
therefore possible that estrogen potentiates the nociceptive effects of inflammation 
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through increased excitability.  In terms of trigeminal pain disorders, the data suggest 
that circulating estrogen increases the excitability of trigeminal afferents and leads to 
exaggerated nociceptive input from inflammation. This may result in pain from 
normally sub-threshold inflammatory processes. 
 
The second goal of this project was to investigate whether ERK activation 
plays a role in estrogen-modified nociception.  Data show that either estrogen or 
inflammation in the region of the masseter increase ERK activation in the trigeminal 
ganglion.  Moreover, estrogen and inflammation combined produce an additive effect 
on ERK activation in trigeminal neurons.  Building upon previous reports, which 
showed that estrogen activates ERK in cultured sensory neurons (Purves-Tyson and 
Keast, 2004; Puri et al., 2006), the results demonstrate that estrogen activates ERK 
in the trigeminal ganglion in vivo.  Furthermore, as delivery of an ERK pathway 
inhibitor to the trigeminal ganglion reduces facial sensitization, the data show that 
peripheral ERK activation within trigeminal ganglion neurons is an important 
component of sensitization of the orofacial region.  Taken together, the data provide 
a mechanism linking high estrogen states and increases in excitability of trigeminal 
ganglion neurons and suggest that estrogen potentiates nociception by increasing 
excitability through ERK activation. 
An important aspect of these results is that antagonizing ERK activation 
reduces secondary allodynia, which crosses dermatomal borders. This finding 
challenges the dogma of trigeminal allodynia, which proposes that secondary 
allodynia is an indication of central sensitization. This mechanism is hypothesized to 
occur when input from sensitized first-order trigeminal afferents sensitizes second-
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order neurons in the trigeminal nucleus caudalis, lowering the activation threshold of 
convergent first-order neurons.  In the trigeminal system, data showing that chemical 
stimulation of dural afferents enhances the responses of second order nucleus 
caudalis neurons to stimulation of facial skin have been taken to indicate central 
sensitization (Burstein et al., 1998).  The current observation that secondary 
allodynia is ameliorated by blocking ERK activation in the trigeminal ganglion after 
the development of central sensitization calls this interpretation into question, and 
suggests that processes in the periphery are involved in maintaining secondary 
allodynia.   
The data from experiments in this proposal support a cascade of events in 
which inflammation of the masseter increases ERK activation outside the third 
division of the trigeminal ganglion.  This is an intriguing finding, as it shows that 
peripheral inflammation can activate ERK in cell bodies that have no direct chemical 
or electrical contact with the inflamed tissue. These results suggest that ERK 
activation can occur through intercellular communication within the ganglion and 
provide a mechanism by which secondary allodynia can occur independent of central 
sensitization.  
The results in this dissertation are significant to our understanding of the 
pathogenesis of cutaneous facial allodynia, as they provide evidence that it arises at 
least in part from processes within the trigeminal ganglion.  While there is certainly a 
contribution of central sensitization in development of allodynia, our data provide 
evidence that it is not a complete explanation.  The presence of allodynia across 
trigeminal dermatomes alone can no longer be said to demonstrate central 
sensitization.  Conversely, the existence of central sensitization does not preclude 
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the contribution of intra-ganglionic mechanisms.  Intra-ganglionic sensitization may 
function in conjunction with central sensitization in the generalization of pain during 
the course of a trigeminal pain episode.   
 
 
 
 
 
Figure IV-1.  Proposed mechanism of 
secondary allodynia.   Inflammation in  
V3 (A) leads to ERK activation in V3 
neurons (B) which communicate (arrow) 
with V2 neurons (C).  Signals from V3 
and estrogen (E2) enhance ERK 
activation in the V2 neuron, lowering the 
nociceptive threshold of the region 
innervated by V2 (D). 
 
 
A possible mechanism for secondary allodynia is shown in the schematic 
(Figure IV-1).   Inflammation in V3 leads to ERK activation in the cell body of a V3 
neuron.   The signal is transmitted to a V2 neuron, activating ERK, through a process 
that may involve communication through gap junctions or local release of 
neurotransmitters.  In the presence of estrogen, there is increased ERK activation 
and increased excitability of the V2 neuron.  That process lowers the threshold of V2 
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nociceptors, and a previously innocuous mechanical stimulus presented to the 
whisker pad results in nociception. 
Taken together, the data suggest that estrogen increases secondary 
sensitization by broadening the sensitized area and that this occurs through ERK 
activation in the trigeminal ganglion. These results suggest the possibility that 
modulation of signal transduction pathways in the periphery following the 
development of central sensitization may be a useful avenue in the management of 
trigeminal pain.   
 
The third goal of this project was to determine which estrogen receptors in 
the trigeminal ganglion function in ERK activation and estrogen-modified nociception. 
The results demonstrate that GPR30 is present in the trigeminal ganglion and is 
localized to nociceptors. GPR30 and ERα are present in distinct, but partially 
overlapping, neuronal populations, and the majority of small trigeminal neurons 
express one of these receptors.  Expression of at least one estrogen receptor by the 
majority of nociceptors in the trigeminal ganglion suggests a basis for the high 
sensitivity of the trigeminal system to the effects of estrogen on nociception. 
Behavioral data show that activation of either GPR30 or ERα using selective 
agonists enhances secondary mechanical allodynia of the orofacial region. The 
results demonstrate that the pro-nociceptive effects of estrogen in the trigeminal 
system can be mediated by either GPR30 or ERα.  Furthermore, we demonstrate 
that either GPR30 or ERα can activate ERK in cultured trigeminal ganglion neurons.  
In light of our previous results showing that ERK activation in the trigeminal ganglion 
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is a mediator of sensitization, the results provide a mechanism by which ERα and 
GPR30 mediate trigeminal sensitization.   
By identifying GPR30 as a putative modulator of sensitization in the 
trigeminal system, the results provide evidence that pro-nociceptive effects of 
estrogen in the trigeminal system are more complex than was previously believed.  
The presence of GPR30 in the trigeminal ganglion presents a novel pathway through 
which estrogen may modulate the activity of sensory neurons, and which is likely 
relevant to the effects of hormonal fluctuations on migraine and facial pain.   
The data provide evidence that peripheral inflammation increases expression 
of GPR30 but not ERα in the trigeminal ganglion, while estrogen increases 
expression of ERα but not GPR30.  Differential regulation of GPR30 and ERα may 
contribute to increased pain during periods of falling estrogen.  In the setting of 
peripheral inflammation, estrogen signaling would shift in the direction of GPR30.  
Falling serum estrogen concentrations, by decreasing ERα expression, would also 
shift estrogen signaling toward GPR30.  Since the neuronal populations that express 
ERα and GPR30 are largely distinct, a decrease in serum estrogen concentration 
during ongoing peripheral inflammation would render the population expressing 
GPR30, predominately nociceptors, more responsive to estrogen, leading to 
sensitization.   
Taken together the results suggest that both the novel estrogen receptor 
GPR30 and ERα participate in estrogen-modified nociception through the activation 
of ERK. Differential regulation of these receptors may have important implications for 
modulation of trigeminal pain by estrogen. 
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